US5882330A
(en)
*
|
1984-05-25 |
1999-03-16 |
Lemelson; Jerome H. |
Drugs and methods for treating diseases
|
US5456663A
(en)
*
|
1984-05-25 |
1995-10-10 |
Lemelson; Jerome H. |
Drugs and methods for treating diseases
|
US5925375A
(en)
*
|
1987-05-22 |
1999-07-20 |
The Liposome Company, Inc. |
Therapeutic use of multilamellar liposomal prostaglandin formulations
|
JPH0720857B2
(ja)
*
|
1988-08-11 |
1995-03-08 |
テルモ株式会社 |
リポソームおよびその製法
|
US6132763A
(en)
*
|
1988-10-20 |
2000-10-17 |
Polymasc Pharmaceuticals Plc |
Liposomes
|
GB8824593D0
(en)
*
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Liposomes
|
US5153000A
(en)
*
|
1988-11-22 |
1992-10-06 |
Kao Corporation |
Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
|
US5356633A
(en)
*
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
US20010051183A1
(en)
*
|
1989-10-20 |
2001-12-13 |
Alza Corporation |
Liposomes with enhanced circulation time and method of treatment
|
US5013556A
(en)
*
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5843473A
(en)
*
|
1989-10-20 |
1998-12-01 |
Sequus Pharmaceuticals, Inc. |
Method of treatment of infected tissues
|
US5620689A
(en)
*
|
1989-10-20 |
1997-04-15 |
Sequus Pharmaceuuticals, Inc. |
Liposomes for treatment of B-cell and T-cell disorders
|
US5527528A
(en)
*
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
US6088613A
(en)
*
|
1989-12-22 |
2000-07-11 |
Imarx Pharmaceutical Corp. |
Method of magnetic resonance focused surgical and therapeutic ultrasound
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
US5773024A
(en)
*
|
1989-12-22 |
1998-06-30 |
Imarx Pharmaceutical Corp. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US6551576B1
(en)
|
1989-12-22 |
2003-04-22 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US5733572A
(en)
*
|
1989-12-22 |
1998-03-31 |
Imarx Pharmaceutical Corp. |
Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
|
US5542935A
(en)
*
|
1989-12-22 |
1996-08-06 |
Imarx Pharmaceutical Corp. |
Therapeutic delivery systems related applications
|
US5705187A
(en)
*
|
1989-12-22 |
1998-01-06 |
Imarx Pharmaceutical Corp. |
Compositions of lipids and stabilizing materials
|
US5352435A
(en)
*
|
1989-12-22 |
1994-10-04 |
Unger Evan C |
Ionophore containing liposomes for ultrasound imaging
|
US5469854A
(en)
*
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
US5305757A
(en)
*
|
1989-12-22 |
1994-04-26 |
Unger Evan C |
Gas filled liposomes and their use as ultrasonic contrast agents
|
US6146657A
(en)
|
1989-12-22 |
2000-11-14 |
Imarx Pharmaceutical Corp. |
Gas-filled lipid spheres for use in diagnostic and therapeutic applications
|
US5776429A
(en)
*
|
1989-12-22 |
1998-07-07 |
Imarx Pharmaceutical Corp. |
Method of preparing gas-filled microspheres using a lyophilized lipids
|
US5441746A
(en)
*
|
1989-12-22 |
1995-08-15 |
Molecular Bioquest, Inc. |
Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
|
US5580575A
(en)
*
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
US6001335A
(en)
*
|
1989-12-22 |
1999-12-14 |
Imarx Pharmaceutical Corp. |
Contrasting agents for ultrasonic imaging and methods for preparing the same
|
US5922304A
(en)
*
|
1989-12-22 |
1999-07-13 |
Imarx Pharmaceutical Corp. |
Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
|
US5656211A
(en)
*
|
1989-12-22 |
1997-08-12 |
Imarx Pharmaceutical Corp. |
Apparatus and method for making gas-filled vesicles of optimal size
|
US5882678A
(en)
*
|
1990-01-12 |
1999-03-16 |
The Liposome Co, Inc. |
Interdigitation-fusion liposomes containing arachidonic acid metabolites
|
US5162361A
(en)
*
|
1990-04-10 |
1992-11-10 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Method of treating diseases associated with elevated levels of interleukin 1
|
US6465188B1
(en)
*
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
US20060084797A1
(en)
*
|
1990-06-11 |
2006-04-20 |
Gilead Sciences, Inc. |
High affinity TGFbeta nucleic acid ligands and inhibitors
|
US20030113369A1
(en)
*
|
1991-01-16 |
2003-06-19 |
Martin Francis J. |
Liposomes with enhanced circulation time and method of treatment
|
US5874062A
(en)
*
|
1991-04-05 |
1999-02-23 |
Imarx Pharmaceutical Corp. |
Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
|
US5205290A
(en)
|
1991-04-05 |
1993-04-27 |
Unger Evan C |
Low density microspheres and their use as contrast agents for computed tomography
|
JP3220180B2
(ja)
*
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
薬剤含有タンパク質結合リポソーム
|
GB9111611D0
(en)
*
|
1991-05-30 |
1991-07-24 |
Sandoz Ltd |
Liposomes
|
ES2221920T3
(es)
|
1992-04-03 |
2005-01-16 |
The Regents Of The University Of California |
Sistema de liberacion de polinucleotidos de autoensamblaje que comprende un peptido cationico anfipatico.
|
ZA933926B
(en)
*
|
1992-06-17 |
1994-01-03 |
Amgen Inc |
Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
|
ES2130406T5
(es)
*
|
1992-08-05 |
2003-12-16 |
Meito Sangyo Kk |
Material compuesto de pequeño diametro compuesto de carboxipolisacarido soluble en agua y oxido de hierro magnetico.
|
NL9201722A
(nl)
*
|
1992-10-05 |
1994-05-02 |
Stichting Tech Wetenschapp |
Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.
|
DE4236237A1
(de)
*
|
1992-10-27 |
1994-04-28 |
Behringwerke Ag |
Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
|
US6764693B1
(en)
*
|
1992-12-11 |
2004-07-20 |
Amaox, Ltd. |
Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
|
JP3351476B2
(ja)
*
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
US5395619A
(en)
*
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
AU6368394A
(en)
*
|
1993-03-23 |
1994-10-11 |
Liposome Technology, Inc. |
Polymer-polypeptide composition and method
|
US6326353B1
(en)
*
|
1993-03-23 |
2001-12-04 |
Sequus Pharmaceuticals, Inc. |
Enhanced circulation effector composition and method
|
US6180134B1
(en)
*
|
1993-03-23 |
2001-01-30 |
Sequus Pharmaceuticals, Inc. |
Enhanced ciruclation effector composition and method
|
WO1994026251A1
(en)
*
|
1993-05-07 |
1994-11-24 |
Sequus Pharmaceuticals, Inc. |
Subcutaneous liposome delivery method
|
US6191105B1
(en)
|
1993-05-10 |
2001-02-20 |
Protein Delivery, Inc. |
Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
|
US5681811A
(en)
*
|
1993-05-10 |
1997-10-28 |
Protein Delivery, Inc. |
Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
|
US5359030A
(en)
*
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
US20050181976A1
(en)
*
|
1993-05-10 |
2005-08-18 |
Ekwuribe Nnochiri N. |
Amphiphilic oligomers
|
WO1994027580A1
(en)
*
|
1993-05-21 |
1994-12-08 |
The Liposome Company, Inc. |
Reduction of liposome-induced adverse physiological reactions
|
US5744155A
(en)
*
|
1993-08-13 |
1998-04-28 |
Friedman; Doron |
Bioadhesive emulsion preparations for enhanced drug delivery
|
US5514670A
(en)
*
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
DK0725629T3
(da)
*
|
1993-10-25 |
2000-08-07 |
Liposome Co Inc |
Liposomale defensiner
|
US5415869A
(en)
*
|
1993-11-12 |
1995-05-16 |
The Research Foundation Of State University Of New York |
Taxol formulation
|
US5468499A
(en)
*
|
1993-11-15 |
1995-11-21 |
Ohio State University |
Liposomes containing the salt of phosphoramide mustard and related compounds
|
US7083572B2
(en)
*
|
1993-11-30 |
2006-08-01 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Therapeutic delivery systems
|
JPH09506866A
(ja)
*
|
1993-12-14 |
1997-07-08 |
ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン |
医薬として活性のある物質の免疫療法のための放出制御
|
US6773719B2
(en)
*
|
1994-03-04 |
2004-08-10 |
Esperion Luv Development, Inc. |
Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
|
US6312719B1
(en)
*
|
1994-03-04 |
2001-11-06 |
The University Of British Columbia |
Liposome compositions and methods for the treatment of atherosclerosis
|
US20010055581A1
(en)
*
|
1994-03-18 |
2001-12-27 |
Lawrence Tamarkin |
Composition and method for delivery of biologically-active factors
|
US5736121A
(en)
*
|
1994-05-23 |
1998-04-07 |
Imarx Pharmaceutical Corp. |
Stabilized homogenous suspensions as computed tomography contrast agents
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
US5626862A
(en)
|
1994-08-02 |
1997-05-06 |
Massachusetts Institute Of Technology |
Controlled local delivery of chemotherapeutic agents for treating solid tumors
|
US5512294A
(en)
*
|
1994-08-05 |
1996-04-30 |
Li; King C. |
Targeted polymerized liposome contrast agents
|
US6132764A
(en)
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6124439A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockefeller University |
OB polypeptide antibodies and method of making
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6001968A
(en)
*
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US5820873A
(en)
*
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
DE69527206T2
(de)
*
|
1994-09-30 |
2003-02-27 |
Inex Pharmaceuticals Corp |
Mittel zum einbringen polyanionischer materialien in zellen
|
US5885613A
(en)
*
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
JPH10507450A
(ja)
*
|
1994-10-14 |
1998-07-21 |
ザ リポソーム カンパニー、インコーポレーテッド |
エーテル脂質リポソームおよびそれらの治療用の使用
|
CN1080575C
(zh)
*
|
1994-10-14 |
2002-03-13 |
蛋白质传送股份有限公司 |
结合稳定的多肽组合物、其治疗、诊断制剂及其制备和使用方法
|
US6214388B1
(en)
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
US6743779B1
(en)
|
1994-11-29 |
2004-06-01 |
Imarx Pharmaceutical Corp. |
Methods for delivering compounds into a cell
|
US5827531A
(en)
*
|
1994-12-02 |
1998-10-27 |
The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration |
Microcapsules and methods for making
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5795587A
(en)
*
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5830430A
(en)
*
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
IL112834A
(en)
*
|
1995-03-01 |
2000-12-06 |
Yeda Res & Dev |
Pharmaceutical compositions for controlled release of soluble receptors
|
US5658588A
(en)
*
|
1995-03-31 |
1997-08-19 |
University Of Cincinnati |
Fibrinogen-coated liposomes
|
GB9509016D0
(en)
*
|
1995-05-03 |
1995-06-21 |
Royal Free Hosp School Med |
Tissue entrapment
|
US8071737B2
(en)
*
|
1995-05-04 |
2011-12-06 |
Glead Sciences, Inc. |
Nucleic acid ligand complexes
|
US5997898A
(en)
*
|
1995-06-06 |
1999-12-07 |
Imarx Pharmaceutical Corp. |
Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6139819A
(en)
|
1995-06-07 |
2000-10-31 |
Imarx Pharmaceutical Corp. |
Targeted contrast agents for diagnostic and therapeutic use
|
US6231834B1
(en)
|
1995-06-07 |
2001-05-15 |
Imarx Pharmaceutical Corp. |
Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US6521211B1
(en)
|
1995-06-07 |
2003-02-18 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Methods of imaging and treatment with targeted compositions
|
US6673364B1
(en)
|
1995-06-07 |
2004-01-06 |
The University Of British Columbia |
Liposome having an exchangeable component
|
JP4335310B2
(ja)
*
|
1995-06-07 |
2009-09-30 |
ザ ユニバーシティ オブ ブリティッシュ コロンビア |
疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
|
US6033645A
(en)
*
|
1996-06-19 |
2000-03-07 |
Unger; Evan C. |
Methods for diagnostic imaging by regulating the administration rate of a contrast agent
|
JPH11511128A
(ja)
*
|
1995-08-01 |
1999-09-28 |
ノバルティス・アクチエンゲゼルシャフト |
リポソームオリゴヌクレオチド組成物
|
US6107332A
(en)
|
1995-09-12 |
2000-08-22 |
The Liposome Company, Inc. |
Hydrolysis-promoting hydrophobic taxane derivatives
|
US6051600A
(en)
*
|
1995-09-12 |
2000-04-18 |
Mayhew; Eric |
Liposomal hydrolysis-promoting hydrophobic taxane derivatives
|
US5834025A
(en)
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
US5858397A
(en)
*
|
1995-10-11 |
1999-01-12 |
University Of British Columbia |
Liposomal formulations of mitoxantrone
|
EA199800279A1
(ru)
*
|
1995-10-11 |
1999-04-29 |
Талариа Терапьютикс, Инк |
Липосомные композиции и способы их применения
|
US6936439B2
(en)
*
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US20030040467A1
(en)
*
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US5626654A
(en)
|
1995-12-05 |
1997-05-06 |
Xerox Corporation |
Ink compositions containing liposomes
|
US5817856A
(en)
*
|
1995-12-11 |
1998-10-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Radiation-protective phospholipid and method
|
US5789244A
(en)
*
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
US6392069B2
(en)
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
US20040014709A1
(en)
*
|
1996-01-08 |
2004-01-22 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
CA2241564C
(en)
|
1996-01-08 |
2013-09-03 |
Genentech, Inc. |
Wsx receptor and ligands
|
US7002027B1
(en)
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
US6096336A
(en)
*
|
1996-01-30 |
2000-08-01 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
US5908624A
(en)
*
|
1996-06-27 |
1999-06-01 |
Albany Medical College |
Antigenic modulation of cells
|
US5965159A
(en)
|
1996-02-16 |
1999-10-12 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
US6007839A
(en)
*
|
1996-02-16 |
1999-12-28 |
The Liposome Company, Inc. |
Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
|
USRE39042E1
(en)
*
|
1996-02-16 |
2006-03-28 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
US5942246A
(en)
*
|
1996-02-16 |
1999-08-24 |
The Liposome Company, Inc. |
Etherlipid containing multiple lipid liposomes
|
US6667053B1
(en)
|
1996-02-16 |
2003-12-23 |
Elan Pharmaceuticals, Inc. |
D and L etherlipid stereoisomers and liposomes
|
AU2549297A
(en)
|
1996-03-28 |
1997-10-17 |
Board Of Trustees Of The University Of Illinois, The |
Materials and methods for making improved echogenic liposome compositions
|
ATE345682T1
(de)
|
1996-05-01 |
2006-12-15 |
Imarx Pharmaceutical Corp |
In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20050042647A1
(en)
*
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5919480A
(en)
|
1996-06-24 |
1999-07-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomal influenza vaccine composition and method
|
US8007784B1
(en)
|
1996-06-27 |
2011-08-30 |
Albany Medical College |
Antigenic modulation of cells
|
US6284267B1
(en)
|
1996-08-14 |
2001-09-04 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
US7368129B1
(en)
|
1996-08-14 |
2008-05-06 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
WO1998007409A1
(en)
*
|
1996-08-23 |
1998-02-26 |
Sequus Pharmaceuticals, Inc. |
Liposomes containing a cisplatin compound
|
ATE252891T1
(de)
*
|
1996-08-26 |
2003-11-15 |
Transgene Sa |
Kationische lipid-nukleinsäure komplexe
|
US6414139B1
(en)
|
1996-09-03 |
2002-07-02 |
Imarx Therapeutics, Inc. |
Silicon amphiphilic compounds and the use thereof
|
US5846517A
(en)
*
|
1996-09-11 |
1998-12-08 |
Imarx Pharmaceutical Corp. |
Methods for diagnostic imaging using a renal contrast agent and a vasodilator
|
AU736056B2
(en)
*
|
1996-09-11 |
2001-07-26 |
Imarx Pharmaceutical Corp. |
Improved methods for diagnostic imaging using a contrast agent and a vasodilator
|
WO1998016201A1
(en)
*
|
1996-10-11 |
1998-04-23 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
TW520297B
(en)
*
|
1996-10-11 |
2003-02-11 |
Sequus Pharm Inc |
Fusogenic liposome composition and method
|
US6224903B1
(en)
|
1996-10-11 |
2001-05-01 |
Sequus Pharmaceuticals, Inc. |
Polymer-lipid conjugate for fusion of target membranes
|
NZ336539A
(en)
*
|
1996-10-15 |
2000-09-29 |
Liposome Co Inc |
Peptide-lipid conjugates, liposomes and liposomal drug delivery
|
US6339069B1
(en)
*
|
1996-10-15 |
2002-01-15 |
Elan Pharmaceuticalstechnologies, Inc. |
Peptide-lipid conjugates, liposomes and lipsomal drug delivery
|
US6261537B1
(en)
|
1996-10-28 |
2001-07-17 |
Nycomed Imaging As |
Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
|
US20070036722A1
(en)
*
|
1996-10-28 |
2007-02-15 |
Pal Rongved |
Separation processes
|
DE69735354T2
(de)
*
|
1996-10-28 |
2006-11-30 |
Amersham Health As |
Verbesserungen an oder in verbindung mit diagnostischen/therapeutischen verbindungen
|
US6331289B1
(en)
|
1996-10-28 |
2001-12-18 |
Nycomed Imaging As |
Targeted diagnostic/therapeutic agents having more than one different vectors
|
US5827533A
(en)
*
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
WO1998035828A1
(en)
*
|
1997-02-14 |
1998-08-20 |
The Regents Of The University Of California |
Lamellar gels and methods for making and regulating
|
US6090800A
(en)
|
1997-05-06 |
2000-07-18 |
Imarx Pharmaceutical Corp. |
Lipid soluble steroid prodrugs
|
US6537246B1
(en)
|
1997-06-18 |
2003-03-25 |
Imarx Therapeutics, Inc. |
Oxygen delivery agents and uses for the same
|
US6143276A
(en)
*
|
1997-03-21 |
2000-11-07 |
Imarx Pharmaceutical Corp. |
Methods for delivering bioactive agents to regions of elevated temperatures
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
HUP0001256A3
(en)
|
1997-04-03 |
2002-12-28 |
Univ Johns Hopkins Med |
Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, method for making the same and using them
|
AU743758B2
(en)
|
1997-04-07 |
2002-02-07 |
Genentech Inc. |
Anti-VEGF antibodies
|
SI1695985T1
(sl)
|
1997-04-07 |
2011-06-30 |
Genentech Inc |
Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo
|
AU7104598A
(en)
*
|
1997-04-09 |
1998-10-30 |
Philipp Lang |
New technique to monitor drug delivery noninvasively (in vivo)
|
US20020039594A1
(en)
*
|
1997-05-13 |
2002-04-04 |
Evan C. Unger |
Solid porous matrices and methods of making and using the same
|
US6416740B1
(en)
|
1997-05-13 |
2002-07-09 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Acoustically active drug delivery systems
|
JP4656675B2
(ja)
*
|
1997-05-14 |
2011-03-23 |
ユニバーシティー オブ ブリティッシュ コロンビア |
脂質小胞への荷電した治療剤の高率封入
|
DE19724796A1
(de)
*
|
1997-06-06 |
1998-12-10 |
Max Delbrueck Centrum |
Mittel zur Antitumortherapie
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6217886B1
(en)
|
1997-07-14 |
2001-04-17 |
The Board Of Trustees Of The University Of Illinois |
Materials and methods for making improved micelle compositions
|
US6548047B1
(en)
|
1997-09-15 |
2003-04-15 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Thermal preactivation of gaseous precursor filled compositions
|
JP4467789B2
(ja)
|
1997-09-18 |
2010-05-26 |
パシラ ファーマシューティカルズ インコーポレーテッド |
持続放出性リポソーム麻酔組成物
|
US6734171B1
(en)
|
1997-10-10 |
2004-05-11 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating nucleic acids in lipid bilayers
|
US6083923A
(en)
*
|
1997-10-31 |
2000-07-04 |
Isis Pharmaceuticals Inc. |
Liposomal oligonucleotide compositions for modulating RAS gene expression
|
US7229841B2
(en)
*
|
2001-04-30 |
2007-06-12 |
Cytimmune Sciences, Inc. |
Colloidal metal compositions and methods
|
ES2384094T3
(es)
|
1997-11-14 |
2012-06-29 |
Pacira Pharmaceuticals, Inc. |
Producción de liposomas multivesiculares
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
EP2014677A1
(en)
|
1997-11-21 |
2009-01-14 |
Genentech, Inc. |
A-33 related antigens and their pharmacological uses
|
US6787132B1
(en)
*
|
1997-12-04 |
2004-09-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combined chemo-immunotherapy with liposomal drugs and cytokines
|
JP2001524512A
(ja)
*
|
1997-12-04 |
2001-12-04 |
イーサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム |
リポソーム薬物およびサイトカインを用いた組み合せ化学免疫療法
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
US6123923A
(en)
|
1997-12-18 |
2000-09-26 |
Imarx Pharmaceutical Corp. |
Optoacoustic contrast agents and methods for their use
|
US20010003580A1
(en)
|
1998-01-14 |
2001-06-14 |
Poh K. Hui |
Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
|
ATE438720T1
(de)
|
1998-02-04 |
2009-08-15 |
Genentech Inc |
Verwendung des heregulins als epithelzellenwachstumsfaktor
|
WO1999039738A1
(en)
*
|
1998-02-09 |
1999-08-12 |
Bracco Research S.A. |
Targeted delivery of biologically active media
|
US6942859B2
(en)
|
1998-03-13 |
2005-09-13 |
University Of Southern California |
Red blood cells covalently bound with polymers
|
US6312685B1
(en)
|
1998-03-13 |
2001-11-06 |
Timothy C. Fisher |
Red blood cells covalently bound with two different polyethylene glycol derivatives
|
ES2313778T3
(es)
|
1998-03-17 |
2009-03-01 |
Genentech, Inc. |
Polipeptidos homologos de vegf y de bmp1.
|
US6433012B1
(en)
*
|
1998-03-25 |
2002-08-13 |
Large Scale Biology Corp. |
Method for inhibiting inflammatory disease
|
WO1999048495A1
(en)
*
|
1998-03-25 |
1999-09-30 |
Biosource Technologies, Inc. |
Benzoates derivatives for inhibiting angiogenesis
|
US6858706B2
(en)
*
|
1998-04-07 |
2005-02-22 |
St. Jude Children's Research Hospital |
Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
|
US6593294B1
(en)
*
|
1998-04-27 |
2003-07-15 |
Opperbas Holding B.V. |
Pharmaceutical composition comprising Factor VIII and neutral liposomes
|
US6986902B1
(en)
*
|
1998-04-28 |
2006-01-17 |
Inex Pharmaceuticals Corporation |
Polyanionic polymers which enhance fusogenicity
|
US6331407B1
(en)
|
1998-05-06 |
2001-12-18 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
US6448224B1
(en)
|
1998-05-06 |
2002-09-10 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
US6169078B1
(en)
*
|
1998-05-12 |
2001-01-02 |
University Of Florida |
Materials and methods for the intracellular delivery of substances
|
EP1865061A3
(en)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
EP1076703B2
(en)
|
1998-05-15 |
2010-12-15 |
Genentech, Inc. |
Therapeutic uses of il-17 homologous polypeptides
|
ES2395693T3
(es)
|
1998-06-12 |
2013-02-14 |
Genentech, Inc. |
Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la fabricación de los mismos
|
US6726925B1
(en)
*
|
1998-06-18 |
2004-04-27 |
Duke University |
Temperature-sensitive liposomal formulation
|
US6200598B1
(en)
*
|
1998-06-18 |
2001-03-13 |
Duke University |
Temperature-sensitive liposomal formulation
|
US20040229363A1
(en)
*
|
1998-06-24 |
2004-11-18 |
Ed Nolan |
High efficiency transfection based on low electric field strength, long pulse length
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
US6277413B1
(en)
|
1998-07-17 |
2001-08-21 |
Skyepharma, Inc. |
Biodegradable compositions for the controlled release of encapsulated substances
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US6703381B1
(en)
|
1998-08-14 |
2004-03-09 |
Nobex Corporation |
Methods for delivery therapeutic compounds across the blood-brain barrier
|
EP1121102B1
(en)
*
|
1998-09-16 |
2003-04-23 |
Alza Corporation |
Liposome-entrapped topoisomerase inhibitors
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6419709B1
(en)
|
1998-10-02 |
2002-07-16 |
Guilford Pharmaceuticals, Inc. |
Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
|
US6153212A
(en)
*
|
1998-10-02 |
2000-11-28 |
Guilford Pharmaceuticals Inc. |
Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
|
KR100719202B1
(ko)
*
|
1998-10-23 |
2007-05-16 |
키린-암젠 인코포레이티드 |
MPl 수용체에 결합하는 화합물 및 이를 함유하는 제약학적 조성물
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
CA2350599A1
(en)
*
|
1998-11-20 |
2000-06-02 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
US6773911B1
(en)
*
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
DK1140173T4
(da)
|
1998-12-22 |
2013-06-10 |
Genentech Inc |
Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
|
EP2075335A3
(en)
|
1998-12-22 |
2009-09-30 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
US6350464B1
(en)
*
|
1999-01-11 |
2002-02-26 |
Guilford Pharmaceuticals, Inc. |
Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
|
US6818227B1
(en)
*
|
1999-02-08 |
2004-11-16 |
Alza Corporation |
Liposome composition and method for administration of a radiosensitizer
|
US6537585B1
(en)
|
1999-03-26 |
2003-03-25 |
Guilford Pharmaceuticals, Inc. |
Methods and compositions for treating solid tumors
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US7112337B2
(en)
|
1999-04-23 |
2006-09-26 |
Alza Corporation |
Liposome composition for delivery of nucleic acid
|
ATE259231T1
(de)
*
|
1999-04-29 |
2004-02-15 |
Alza Corp |
Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung
|
CA2270600A1
(en)
|
1999-05-03 |
2000-11-03 |
Infectio Recherche Inc. |
Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
|
EP1645290A1
(en)
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
AU4430200A
(en)
*
|
1999-05-11 |
2000-11-21 |
Sankyo Company Limited |
Liposome preparation of fat-soluble antitumor drug
|
US20040023874A1
(en)
*
|
2002-03-15 |
2004-02-05 |
Burgess Catherine E. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US6974684B2
(en)
*
|
2001-08-08 |
2005-12-13 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040229779A1
(en)
*
|
1999-05-14 |
2004-11-18 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040067490A1
(en)
*
|
2001-09-07 |
2004-04-08 |
Mei Zhong |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
DE60043367D1
(de)
|
1999-06-15 |
2009-12-31 |
Genentech Inc |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
US20030021792A1
(en)
*
|
2001-06-08 |
2003-01-30 |
Roben Paul W. |
Tissue-specific endothelial membrane proteins
|
US7169889B1
(en)
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
US6309633B1
(en)
|
1999-06-19 |
2001-10-30 |
Nobex Corporation |
Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
|
CA2376849C
(en)
*
|
1999-06-24 |
2008-10-14 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of inhibiting leakage of drug encapsulated in liposomes
|
AT500848B1
(de)
|
1999-06-25 |
2008-01-15 |
Genentech Inc |
Humanisierte anti-erbb2-antikörper
|
US6352996B1
(en)
|
1999-08-03 |
2002-03-05 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
BR0013814A
(pt)
|
1999-08-27 |
2002-04-23 |
Genentech Inc |
Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2
|
NZ523206A
(en)
*
|
1999-08-31 |
2004-12-24 |
Genentech Inc |
Antibodies that bind to tumor gene sequences
|
CA2349406C
(en)
*
|
1999-09-03 |
2011-01-11 |
Amgen Inc. |
Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
|
WO2001026625A2
(en)
|
1999-10-08 |
2001-04-19 |
Alza Corp |
Neutral-cationic lipid for nucleic acid and drug delivery
|
IT1315253B1
(it)
*
|
1999-10-22 |
2003-02-03 |
Novuspharma Spa |
Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US6511676B1
(en)
*
|
1999-11-05 |
2003-01-28 |
Teni Boulikas |
Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
|
WO2001039722A2
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
CA2391455A1
(en)
|
1999-12-01 |
2001-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6593308B2
(en)
|
1999-12-03 |
2003-07-15 |
The Regents Of The University Of California |
Targeted drug delivery with a hyaluronan ligand
|
WO2001041738A2
(en)
*
|
1999-12-10 |
2001-06-14 |
Celator Technologies Inc. |
Lipid carrier compositions with protected surface reactive functions
|
DK1897945T3
(da)
|
1999-12-23 |
2012-05-07 |
Genentech Inc |
IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
|
CA2395132A1
(en)
*
|
2000-01-05 |
2001-07-12 |
Imarx Therapeutics, Inc. |
Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
CN1425066B
(zh)
*
|
2000-01-13 |
2010-05-26 |
杰南技术公司 |
新的stra6多肽
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
JP2003521366A
(ja)
*
|
2000-01-28 |
2003-07-15 |
アルザ・コーポレーション |
過飽和溶液中に取り込まれた化合物を含有するリポソーム
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
JP4922824B2
(ja)
*
|
2000-04-03 |
2012-04-25 |
参天製薬株式会社 |
送達性物質およびそれを利用した薬物デリバリーシステム
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
ATE382333T1
(de)
*
|
2000-04-12 |
2008-01-15 |
Liplasome Pharma As |
Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen
|
ATE319737T1
(de)
|
2000-04-21 |
2006-03-15 |
Amgen Inc |
Peptidderivate des apolipoproteins-a1/aii
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
WO2001085131A2
(en)
*
|
2000-05-11 |
2001-11-15 |
Celator Technologies Inc. |
Lipid carrier compositions for improved drug retention
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
AU6531101A
(en)
|
2000-06-02 |
2001-12-17 |
Genentech Inc |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
CA2410906C
(en)
|
2000-06-02 |
2012-10-02 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (ec)-drug conjugates
|
US20030072794A1
(en)
*
|
2000-06-09 |
2003-04-17 |
Teni Boulikas |
Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
|
JP2004512262A
(ja)
|
2000-06-20 |
2004-04-22 |
アイデック ファーマスーティカルズ コーポレイション |
非放射性抗cd20抗体/放射標識抗cd22抗体の組合せ
|
CA2709771A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US20040023259A1
(en)
*
|
2000-07-26 |
2004-02-05 |
Luca Rastelli |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
ATE412009T1
(de)
|
2000-08-24 |
2008-11-15 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030133972A1
(en)
*
|
2000-10-11 |
2003-07-17 |
Targesome, Inc. |
Targeted multivalent macromolecules
|
EP1421174B1
(en)
|
2000-10-18 |
2009-12-23 |
The Brigham And Women's Hospital, Inc. |
Hematopoietic cell e-selectin/l-selectin ligand polypeptides and methods of use thereof
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
AU2002225878A1
(en)
*
|
2000-11-02 |
2002-05-15 |
Smith Kline Beecham Corporation |
Receptor antagonist-lipid conjugates and delivery vehicles containing same
|
DE10056136A1
(de)
*
|
2000-11-07 |
2002-05-16 |
Nemod New Modalities |
Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
|
AU2002239607A1
(en)
*
|
2000-11-30 |
2002-06-11 |
Baxter Healthcare Corporation |
Ahf associated dispersion system and method for preparation
|
US7625584B2
(en)
*
|
2000-11-30 |
2009-12-01 |
The Research Foundation Of State University Of New York |
Method of complexing a protein by the use of a dispersed system and proteins thereof
|
US8110218B2
(en)
*
|
2000-11-30 |
2012-02-07 |
The Research Foundation Of State University Of New York |
Compositions and methods for less immunogenic protein-lipid complexes
|
WO2002061036A2
(en)
*
|
2000-11-30 |
2002-08-08 |
The Research Foundation Of State University Of New York |
Method of complexing a protein by the use of a dispersed system and proteins thereof
|
US20060014674A1
(en)
|
2000-12-18 |
2006-01-19 |
Dennis Keith |
Methods for preparing purified lipopeptides
|
EP1343811A4
(en)
*
|
2000-12-18 |
2004-12-08 |
Cubist Pharm Inc |
PROCESSES FOR THE PREPARATION OF PURIFIED LIPOPEPTIDES
|
WO2002059145A1
(en)
*
|
2000-12-18 |
2002-08-01 |
Cubist Pharmaceuticals, Inc. |
Methods for preparing purified lipopeptides
|
US20040077604A1
(en)
*
|
2001-12-19 |
2004-04-22 |
Lenard Lichtenberger |
Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
|
US6964849B2
(en)
|
2001-01-11 |
2005-11-15 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
US20040043928A1
(en)
*
|
2001-08-02 |
2004-03-04 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
AR035779A1
(es)
|
2001-02-06 |
2004-07-14 |
Genetics Inst Llc |
Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
CA2439953A1
(en)
*
|
2001-03-08 |
2002-09-19 |
Mark D. Bednarski |
Stabilized therapeutic and imaging agents
|
AU2002305094B2
(en)
*
|
2001-03-26 |
2007-01-11 |
Alza Corporation |
Liposome composition for improved intracellular delivery of a therapeutic agent
|
US20040126900A1
(en)
*
|
2001-04-13 |
2004-07-01 |
Barry Stephen E |
High affinity peptide- containing nanoparticles
|
EP1383480A4
(en)
*
|
2001-04-30 |
2006-05-24 |
Targeted Genetics Corp |
Lipid-Containing Drug Delivery Complexes and Method of Producing the Same
|
US20030077829A1
(en)
*
|
2001-04-30 |
2003-04-24 |
Protiva Biotherapeutics Inc.. |
Lipid-based formulations
|
GB0111279D0
(en)
*
|
2001-05-10 |
2001-06-27 |
Nycomed Imaging As |
Radiolabelled liposomes
|
EA010435B1
(ru)
|
2001-05-11 |
2008-08-29 |
Амген, Инк. |
Связывающиеся с tall-1 молекулы и их применение
|
JP2004528384A
(ja)
*
|
2001-05-15 |
2004-09-16 |
トランジェーヌ、ソシエテ、アノニム |
目的の物質を細胞中に導入するための複合体
|
US20020197253A1
(en)
*
|
2001-05-22 |
2002-12-26 |
Cheek Dennis J. |
Compositions and methods for promoting or inhibiting NDPK
|
CA2448018A1
(en)
*
|
2001-05-22 |
2002-11-28 |
Duke University |
Compositions and methods for inhibiting metastasis
|
EP2340849A1
(en)
|
2001-05-30 |
2011-07-06 |
Genentech, Inc. |
Anti-NGF antibodies for the treatment of various disorders
|
IL158819A0
(en)
*
|
2001-05-31 |
2004-05-12 |
Skyepharma Inc |
Encapsulation of nanosuspensions in liposomes and microspheres
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
*
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
KR100628425B1
(ko)
|
2001-06-20 |
2006-09-28 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
WO2003000707A2
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
CN1827766B
(zh)
|
2001-06-28 |
2010-08-25 |
徐荣祥 |
体外细胞的培养方法
|
US20030087274A1
(en)
*
|
2001-07-05 |
2003-05-08 |
Anderson David W. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040029790A1
(en)
*
|
2001-07-05 |
2004-02-12 |
Meera Patturajan |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
WO2003007915A2
(en)
*
|
2001-07-19 |
2003-01-30 |
Guilford Pharmaceuticals, Inc. |
Compositions for treatment of head and neck cancers, and methods of making and using the same
|
US20030133903A1
(en)
*
|
2001-07-19 |
2003-07-17 |
Wenbin Dang |
Compositions for treatment of prostate cancers and methods of making and using the same
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
CN1310672C
(zh)
*
|
2001-07-29 |
2007-04-18 |
耶路撒冷希伯来大学伊森姆研究发展公司 |
作为造血刺激物的成骨生长寡肽
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US20040030096A1
(en)
*
|
2001-08-02 |
2004-02-12 |
Linda Gorman |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
EP1424889A4
(en)
*
|
2001-08-20 |
2008-04-02 |
Transave Inc |
PROCESS FOR TREATING LUNG CANCERS
|
IL160307A0
(en)
|
2001-08-31 |
2004-07-25 |
Univ Rockefeller |
Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US6913903B2
(en)
*
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7166571B2
(en)
*
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7312192B2
(en)
*
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7547673B2
(en)
*
|
2001-09-13 |
2009-06-16 |
The Johns Hopkins University |
Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
|
NZ573831A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
YU26304A
(sh)
*
|
2001-09-28 |
2006-08-17 |
Esperion Therapeutics Inc. |
Postupci i uređaji za ekstruziju vezikula pod visokim pritiskom
|
DE10148065A1
(de)
*
|
2001-09-28 |
2003-04-17 |
Max Planck Gesellschaft |
(Ester)-Lysolecithine in Liposomen
|
US20030199442A1
(en)
*
|
2001-10-09 |
2003-10-23 |
Alsobrook John P. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
AU2002368202B2
(en)
|
2001-11-02 |
2008-06-05 |
Insert Therapeutics, Inc |
Methods and compositions for therapeutic use of RNA interference
|
WO2003039595A2
(en)
*
|
2001-11-07 |
2003-05-15 |
Inex Pharmaceuticals Corporation |
Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
|
US20040219201A1
(en)
*
|
2001-12-06 |
2004-11-04 |
Yechezkel Barenholz |
Tempamine compositions and methods of use
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
MXPA04006554A
(es)
|
2002-01-02 |
2005-03-31 |
Genentech Inc |
Composiciones y metodos para diagnostico y tratamiento de tumor.
|
US7910586B2
(en)
|
2002-01-04 |
2011-03-22 |
The Rockefeller University |
Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders
|
US7781396B2
(en)
*
|
2002-01-31 |
2010-08-24 |
Tel Aviv University Future Technology Development L.P. |
Peptides directed for diagnosis and treatment of amyloid-associated disease
|
US20040052928A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Ehud Gazit |
Peptides and methods using same for diagnosing and treating amyloid-associated diseases
|
US6929798B2
(en)
|
2002-02-13 |
2005-08-16 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
CA2476518A1
(en)
|
2002-02-22 |
2003-09-04 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
EP1571968A4
(en)
|
2002-04-16 |
2007-10-17 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
|
AU2003233008B2
(en)
*
|
2002-04-22 |
2008-04-24 |
Recopharma Ab |
Fusion polypeptides and methods for inhibiting microbial adhesion
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
WO2005056606A2
(en)
*
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Optimized antibodies that target the epidermal growth factor receptor
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7601688B2
(en)
*
|
2002-06-13 |
2009-10-13 |
Biocon Limited |
Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
|
JP4722481B2
(ja)
|
2002-06-28 |
2011-07-13 |
プロティバ バイオセラピューティクス リミテッド |
リポソーム製造方法および装置
|
DE60335469D1
(de)
*
|
2002-07-02 |
2011-02-03 |
Univ Texas |
Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
|
US20050169979A1
(en)
*
|
2002-07-03 |
2005-08-04 |
Dov Michaeli |
Liposomal vaccine
|
US20040247661A1
(en)
*
|
2002-07-03 |
2004-12-09 |
Dov Michaeli |
Liposomal vaccine
|
EP1528915A2
(en)
*
|
2002-07-03 |
2005-05-11 |
Aphton Corporation |
Liposomal vaccine
|
EP2383278A1
(en)
|
2002-07-08 |
2011-11-02 |
Genentech, Inc. |
Method to determine B cell mediated diseases
|
US7622118B2
(en)
*
|
2002-07-15 |
2009-11-24 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using selected antibodies to aminophospholipids
|
US7714109B2
(en)
*
|
2002-07-15 |
2010-05-11 |
Board Of Regents, The University Of Texas System |
Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
|
US7572448B2
(en)
*
|
2002-07-15 |
2009-08-11 |
Board Of Regents, The University Of Texas System |
Combined cancer treatment methods using selected antibodies to aminophospholipids
|
US7615223B2
(en)
*
|
2002-07-15 |
2009-11-10 |
Board Of Regents, The University Of Texas System |
Selected immunoconjugates for binding to aminophospholipids
|
US7678386B2
(en)
*
|
2002-07-15 |
2010-03-16 |
Board Of Regents The University Of Texas |
Liposomes coated with selected antibodies that bind to aminophospholipids
|
US7625563B2
(en)
*
|
2002-07-15 |
2009-12-01 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
|
SI2269656T1
(sl)
*
|
2002-07-15 |
2014-11-28 |
Board Of Regents, The University Of Texas System |
Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
|
CA2490758C
(en)
|
2002-07-15 |
2014-09-23 |
Genentech, Inc. |
Dosage form of recombinant humanized monoclonal antibody 2c4
|
WO2004007693A2
(en)
*
|
2002-07-16 |
2004-01-22 |
University Of South Florida |
Human immunosuppressive protein
|
US20040161423A1
(en)
*
|
2002-07-18 |
2004-08-19 |
Sanjeev Kumar (Mendiratta) |
Polymer modified anti-angiogenic serpins
|
CA2494673A1
(en)
*
|
2002-08-02 |
2004-07-01 |
Transave, Inc. |
Platinum aggregates and process for producing the same
|
US9186322B2
(en)
*
|
2002-08-02 |
2015-11-17 |
Insmed Incorporated |
Platinum aggregates and process for producing the same
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
EP1393720A1
(en)
*
|
2002-08-27 |
2004-03-03 |
Universiteit Utrecht |
Vesicle-encapsulated corticosteroids for treatment of cancer
|
MXPA05002219A
(es)
|
2002-08-28 |
2005-07-05 |
Immunex Corp |
Composiciones y metodos para tratar una enfermedad cardiovascular.
|
AR036316A1
(es)
*
|
2002-08-29 |
2004-08-25 |
Monte Verde S A |
Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion
|
US20070231379A1
(en)
*
|
2002-08-29 |
2007-10-04 |
Slater James L |
Liposome-entrapped topoisomerase inhibitors
|
US20080214437A1
(en)
*
|
2002-09-06 |
2008-09-04 |
Mohapatra Shyam S |
Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
|
WO2004022003A2
(en)
|
2002-09-06 |
2004-03-18 |
University Of South Florida |
Materials and methods for treatment of allergic diseases
|
US8071560B2
(en)
*
|
2004-02-17 |
2011-12-06 |
University Of South Florida |
Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
|
ATE493433T1
(de)
|
2002-09-11 |
2011-01-15 |
Genentech Inc |
Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
|
EP1578373A4
(en)
|
2002-09-11 |
2007-10-24 |
Genentech Inc |
NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
|
AU2003267785C1
(en)
*
|
2002-09-13 |
2009-12-24 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
EP1578364A4
(en)
|
2002-09-16 |
2011-06-08 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
EP1585482A4
(en)
|
2002-09-25 |
2009-09-09 |
Genentech Inc |
NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
|
EP2272958A1
(en)
|
2002-09-26 |
2011-01-12 |
ISIS Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
DK2345671T3
(en)
|
2002-09-27 |
2016-02-15 |
Xencor Inc |
Optimized Fc variants and methods for their formation
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
CA2500901A1
(en)
*
|
2002-10-04 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
AU2003285864C1
(en)
|
2002-10-08 |
2010-07-01 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
|
UA80447C2
(en)
*
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
WO2005000194A2
(en)
|
2002-10-08 |
2005-01-06 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
EP1633786A4
(en)
*
|
2002-10-09 |
2007-07-25 |
Rinat Neuroscience Corp |
METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
|
JP2006517785A
(ja)
|
2002-10-29 |
2006-08-03 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための新規組成物と方法
|
WO2004110345A2
(en)
*
|
2002-10-29 |
2004-12-23 |
Pharmacia Corporation |
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
|
CA2505330A1
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
AU2003287505A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
AU2003295401B2
(en)
|
2002-11-08 |
2010-04-29 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
US20040093198A1
(en)
*
|
2002-11-08 |
2004-05-13 |
Carbon Design Systems |
Hardware simulation with access restrictions
|
US20040152769A1
(en)
*
|
2002-11-09 |
2004-08-05 |
Ekwuribe Nnochiri Nkem |
Modified carbamate-containing prodrugs and methods of synthesizing same
|
EP1569695B1
(en)
|
2002-11-13 |
2013-05-15 |
Genzyme Corporation |
Antisense modulation of apolipoprotein b expression
|
DK1569695T3
(da)
|
2002-11-13 |
2013-08-05 |
Genzyme Corp |
Antisense-modulering af apolipoprotein-b-ekspression
|
US20050158375A1
(en)
*
|
2002-11-15 |
2005-07-21 |
Toshikiro Kimura |
Pharmaceutical composition containing liposomes for treating cancer
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US7648962B2
(en)
*
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
US20070048301A1
(en)
|
2002-11-26 |
2007-03-01 |
Bodary-Winter Sarah C |
Compositions and methods for the treatment of immune related diseases
|
SG159387A1
(en)
|
2002-11-26 |
2010-03-30 |
Biocon Ltd In |
Modified natriuretic compounds, conjugates, and uses thereof
|
US7491699B2
(en)
*
|
2002-12-09 |
2009-02-17 |
Ramot At Tel Aviv University Ltd. |
Peptide nanostructures and methods of generating and using the same
|
EP1587484A4
(en)
*
|
2002-12-19 |
2008-11-12 |
Alza Corp |
METHOD OF TREATING ANGIOGENIC TISSUE GROWTH
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
NZ587852A
(en)
|
2002-12-24 |
2012-02-24 |
Rinat Neuroscience Corp |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
US8980310B2
(en)
*
|
2002-12-31 |
2015-03-17 |
Bharat Serums and Vaccines, Ltd. |
Non-pegylated long-circulating liposomes
|
NZ540778A
(en)
|
2002-12-31 |
2008-04-30 |
Zydus Bsv Res And Dev Private |
Non-pegylated long-circulating liposomes
|
ATE426575T1
(de)
*
|
2003-01-07 |
2009-04-15 |
Univ Ramot |
Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
|
WO2004063216A1
(ja)
*
|
2003-01-10 |
2004-07-29 |
Yamanouchi Pharmaceutical Co., Ltd. |
血中滞留および癌組織特異的薬物送達のためのコンジュゲート
|
US7169892B2
(en)
|
2003-01-10 |
2007-01-30 |
Astellas Pharma Inc. |
Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems
|
DK1597366T3
(da)
|
2003-02-11 |
2013-02-25 |
Antisense Therapeutics Ltd |
Modulering af ekspression af insulin-lignende vækstfaktor receptor I
|
KR20050111598A
(ko)
*
|
2003-02-19 |
2005-11-25 |
리나트 뉴로사이언스 코퍼레이션 |
신경 성장 인자 길항제 및 nsaid를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US7968115B2
(en)
|
2004-03-05 |
2011-06-28 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of cancer
|
WO2004087097A2
(en)
*
|
2003-03-31 |
2004-10-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
KR20060034215A
(ko)
|
2003-03-31 |
2006-04-21 |
알자 코포레이션 |
비대칭 지질 코팅을 가지는 지질 입자 및 그 제조 방법
|
CN1798575A
(zh)
|
2003-04-04 |
2006-07-05 |
健泰科生物技术公司 |
高浓度抗体和蛋白制剂
|
ME00426B
(me)
|
2003-04-09 |
2011-10-10 |
Genentech Inc |
Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
|
ES2307009T3
(es)
*
|
2003-04-15 |
2008-11-16 |
Opperbas Holding B.V. |
Composicion farmaceutica que contiene proteinas y/o polipeptidos y particulas coloidales.
|
US20060246104A1
(en)
*
|
2003-04-16 |
2006-11-02 |
Massia Stephen P |
Stable rgd peptidomimetic composition
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
EP1620112A4
(en)
*
|
2003-04-17 |
2007-04-25 |
Univ Columbia |
DESMOGLEIN 4 IS A NEW GENUS INVOLVED IN HAIR GROWTH
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US7919118B2
(en)
|
2003-05-12 |
2011-04-05 |
Affymax, Inc. |
Spacer moiety for poly (ethylene glycol) modified peptide based compounds
|
EA010016B1
(ru)
|
2003-05-12 |
2008-06-30 |
Афимакс, Инк. |
Новые модифицированные полиэтиленгликолем соединения и их применение
|
AU2004251161A1
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
WO2005000900A1
(en)
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Treatment with anti-vegf antibodies
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
JP2006526661A
(ja)
*
|
2003-06-04 |
2006-11-24 |
カンジ,インコーポレイテッド |
インターフェロン治療のための方法および組成物
|
PT1636593E
(pt)
|
2003-06-06 |
2009-06-03 |
Genentech Inc |
Modulação da interacção entre a cadeia beta de hgf e c-met
|
CN100436480C
(zh)
|
2003-06-11 |
2008-11-26 |
韦思公司 |
血小板糖蛋白IB-α变体融合多肽及其用法
|
US7939058B2
(en)
|
2003-07-03 |
2011-05-10 |
University Of Southern California |
Uses of IL-12 in hematopoiesis
|
ES2354238T3
(es)
|
2003-07-03 |
2011-03-11 |
University Of Medicine And Dentistry Of New Jersey |
Genes como herramienta de diagnóstico para autismo.
|
ES2424353T3
(es)
|
2003-07-08 |
2013-10-01 |
Genentech, Inc. |
Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos
|
CA2532228C
(en)
*
|
2003-07-16 |
2017-02-14 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
CN100431525C
(zh)
*
|
2003-07-17 |
2008-11-12 |
台湾东洋药品工业股份有限公司 |
脂质体悬浮液制造方法及含该法所制脂质体悬浮液的产物
|
CA2534234C
(en)
*
|
2003-07-31 |
2011-02-22 |
The Board Of Regents Of The University Of Texas System |
Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2005016348A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Method of inhibiting immune responses stimulated by an endogenous factor
|
US20050054614A1
(en)
*
|
2003-08-14 |
2005-03-10 |
Diacovo Thomas G. |
Methods of inhibiting leukocyte accumulation
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US8986731B2
(en)
*
|
2003-08-26 |
2015-03-24 |
Biolitec Pharma Marketing Ltd |
Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
|
ATE422880T1
(de)
*
|
2003-08-26 |
2009-03-15 |
Smithkline Beecham Corp |
Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
|
US20060115523A1
(en)
*
|
2004-12-01 |
2006-06-01 |
Konduri Kameswari S |
Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
|
US8846079B1
(en)
|
2004-12-01 |
2014-09-30 |
Vgsk Technologies, Inc. |
Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
|
US11324698B2
(en)
|
2003-08-28 |
2022-05-10 |
Vgsk Technologies, Inc. |
Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
|
EP1666486A4
(en)
*
|
2003-09-03 |
2006-12-06 |
Kyowa Hakko Kogyo Kk |
MODIFIED COMPOUND USING A GLYCEROL DERIVATIVE
|
US20050233435A1
(en)
*
|
2003-09-04 |
2005-10-20 |
Nyu Medical Center |
Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
CN1882693B
(zh)
*
|
2003-09-15 |
2012-08-15 |
普洛体维生物治疗公司 |
聚乙二醇修饰的脂质化合物及其应用
|
NZ545134A
(en)
|
2003-09-18 |
2009-06-26 |
Lilly Co Eli |
Modulation of eIF4E expression
|
JP4917889B2
(ja)
*
|
2003-09-25 |
2012-04-18 |
テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. |
アミロイド関連疾患を処置するための組成物及びその使用方法
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US7625707B2
(en)
*
|
2003-10-02 |
2009-12-01 |
Ramot At Tel Aviv University Ltd. |
Antibacterial agents and methods of identifying and utilizing same
|
ES2437491T3
(es)
|
2003-10-10 |
2014-01-10 |
Alchemia Oncology Pty Limited |
Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad
|
WO2005034979A2
(en)
*
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7960350B2
(en)
|
2003-10-24 |
2011-06-14 |
Ader Enterprises, Inc. |
Composition and method for the treatment of eye disease
|
CA2542804A1
(en)
*
|
2003-10-24 |
2005-05-06 |
Alza Corporation |
Preparation of lipid particles
|
WO2005040163A1
(en)
*
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
US20050129753A1
(en)
*
|
2003-11-14 |
2005-06-16 |
Gabizon Alberto A. |
Method for drug loading in liposomes
|
DE602004021713D1
(de)
*
|
2003-11-14 |
2009-08-06 |
Het Nl Kanker I The Netherland |
Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung
|
JP4901478B2
(ja)
|
2003-11-17 |
2012-03-21 |
ジェネンテック, インコーポレイテッド |
造血系起源の腫瘍の治療のための組成物と方法
|
CN1914226B
(zh)
*
|
2003-11-25 |
2012-02-01 |
达纳-法伯癌症研究院有限公司 |
SARS-CoV抗体及其使用方法
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
EP1692178A1
(en)
|
2003-12-11 |
2006-08-23 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
WO2005062955A2
(en)
|
2003-12-23 |
2005-07-14 |
Rinat Neuroscience Corp. |
Agonist anti-trkc antibodies and methods using same
|
MXPA06007856A
(es)
|
2004-01-07 |
2007-03-23 |
Chiron Corp |
Anticuerpo monoclonal especifico de factor de estimulacion de colonias de macrofagos (m-csf) y usos del mismo.
|
JP2007520481A
(ja)
*
|
2004-01-15 |
2007-07-26 |
アルザ・コーポレーシヨン |
治療薬を送達するためのリポソーム組成物
|
US20050164271A1
(en)
|
2004-01-20 |
2005-07-28 |
Sanjay Bhanot |
Modulation of glucocorticoid receptor expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
WO2005094420A2
(en)
*
|
2004-02-17 |
2005-10-13 |
University Of South Florida |
Materials and methods for treatment of inflammatory and cell proliferation disorders
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
ATE452147T1
(de)
|
2004-02-19 |
2010-01-15 |
Genentech Inc |
Antikörper mit korrigierten cdr
|
US8784881B2
(en)
|
2004-03-05 |
2014-07-22 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of diseases
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP1735009A4
(en)
*
|
2004-03-12 |
2011-03-30 |
Alnylam Pharmaceuticals Inc |
RNAI AGENTS TARGETING THE VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF)
|
EP2700720A3
(en)
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNASE H
|
EP1579850A3
(en)
*
|
2004-03-15 |
2009-12-16 |
Nipro Corporation |
A pharmaceutical composition containing liposomes for treating a cancer
|
CA2559722A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Transave, Inc. |
Administration of cisplatin by inhalation
|
US20070065522A1
(en)
*
|
2004-03-18 |
2007-03-22 |
Transave, Inc. |
Administration of high potency platinum compound formulations by inhalation
|
US8241663B2
(en)
*
|
2004-03-26 |
2012-08-14 |
Terumo Kabushiki Kaisha |
Liposome preparation
|
ES2707393T3
(es)
*
|
2004-03-26 |
2019-04-03 |
Curis Inc |
Moduladores de interferencia de ARN de señalización de hedgehog y usos de los mismos
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
PL1732949T3
(pl)
|
2004-04-07 |
2010-06-30 |
Rinat Neuroscience Corp |
Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
US20060002930A1
(en)
*
|
2004-04-16 |
2006-01-05 |
Genentech, Inc. |
Treatment of disorders
|
US8658203B2
(en)
*
|
2004-05-03 |
2014-02-25 |
Merrimack Pharmaceuticals, Inc. |
Liposomes useful for drug delivery to the brain
|
EP1746976B1
(en)
|
2004-05-03 |
2017-01-11 |
Merrimack Pharmaceuticals, Inc. |
Liposomes useful for drug delivery
|
USRE44638E1
(en)
|
2004-05-13 |
2013-12-10 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
ATE450251T1
(de)
*
|
2004-05-17 |
2009-12-15 |
Tekmira Pharmaceuticals Corp |
Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
|
US20060292554A1
(en)
*
|
2004-05-18 |
2006-12-28 |
Genentech, Inc. |
Major coat protein variants for C-terminal and bi-terminal display
|
US20050260260A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Edward Kisak |
Liposome compositions for the delivery of macromolecules
|
AU2005245018A1
(en)
*
|
2004-05-21 |
2005-12-01 |
Transave, Inc. |
Treatment of lung diseases and pre-lung disease conditions
|
EP1749000A4
(en)
*
|
2004-05-25 |
2009-12-30 |
Metabolex Inc |
BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
|
BRPI0511510A
(pt)
*
|
2004-05-25 |
2007-12-26 |
Metabolex Inc |
composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo
|
CA2567883A1
(en)
*
|
2004-05-25 |
2005-12-15 |
Icos Corporation |
Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
|
US8481501B2
(en)
*
|
2004-05-28 |
2013-07-09 |
Human Biomolecular Research Institute |
Synthesis of metabolically stable analgesics, pain medications and other agents
|
WO2005121372A2
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
JP2008501335A
(ja)
*
|
2004-06-03 |
2008-01-24 |
アイシス ファーマシューティカルズ、インク. |
キメラギャップ化オリゴマー組成物
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
MXPA06014069A
(es)
|
2004-06-04 |
2007-04-25 |
Genentech Inc |
Metodo para tratar esclerosis multiple.
|
JP4796062B2
(ja)
*
|
2004-06-07 |
2011-10-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
脂質封入干渉rna
|
EP1781593B1
(en)
|
2004-06-07 |
2011-12-14 |
Protiva Biotherapeutics Inc. |
Cationic lipids and methods of use
|
CA2579756C
(en)
*
|
2004-06-19 |
2013-04-30 |
Human Biomolecular Research Institute |
Modulators of central nervous system neurotransmitters
|
CA2571243A1
(en)
|
2004-06-21 |
2006-01-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
|
US20060019893A1
(en)
*
|
2004-07-02 |
2006-01-26 |
Genentech, Inc. |
Factor VIIa variants
|
WO2006002538A1
(en)
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory sirna molecules and uses therefor
|
US8143380B2
(en)
*
|
2004-07-08 |
2012-03-27 |
Amgen Inc. |
Therapeutic peptides
|
CN101014619B
(zh)
|
2004-07-15 |
2010-11-03 |
赞科股份有限公司 |
优化的Fc变体
|
WO2006006172A2
(en)
*
|
2004-07-15 |
2006-01-19 |
Ramot At Tel Aviv University Ltd. |
Use of anti-amyloid agents for treating and typing pathogen infections
|
WO2006007712A1
(en)
*
|
2004-07-19 |
2006-01-26 |
Protiva Biotherapeutics, Inc. |
Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
|
UA91512C2
(ru)
*
|
2004-07-19 |
2010-08-10 |
Биокон Лимитед |
Коньюгати олигомеров инсулина, их композиция (варианты) и применение
|
CN102641503A
(zh)
|
2004-07-20 |
2012-08-22 |
健泰科生物技术公司 |
血管生成素样4蛋白抑制剂,组合,以及其用途
|
JP5226308B2
(ja)
|
2004-07-26 |
2013-07-03 |
ジェネンテック, インコーポレイテッド |
肝細胞増殖因子活性化を制御するための方法及び組成物
|
JP5042828B2
(ja)
*
|
2004-07-30 |
2012-10-03 |
ライナット ニューロサイエンス コーポレイション |
アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
|
EP1781310B1
(en)
|
2004-08-02 |
2015-10-14 |
Ramot at Tel Aviv University Ltd. |
Articles of peptide nanostructures and method of forming the same
|
US9132116B2
(en)
*
|
2004-08-02 |
2015-09-15 |
Willowcroft Pharm Inc. |
Mast cell stabilizers to prevent or treat laminitis
|
ES2356748T3
(es)
|
2004-08-17 |
2011-04-12 |
Tyco Healthcare Group Lp |
Barrera anti-adhesión.
|
JP2006056807A
(ja)
*
|
2004-08-18 |
2006-03-02 |
Konica Minolta Medical & Graphic Inc |
光線力学療法製剤
|
US7732479B2
(en)
|
2004-08-19 |
2010-06-08 |
Tel Aviv University Future Technology Development L.P. |
Compositions for treating amyloid associated diseases
|
JP4715133B2
(ja)
*
|
2004-08-26 |
2011-07-06 |
コニカミノルタエムジー株式会社 |
抗腫瘍リポソーム製剤およびその製造方法
|
JP2006069929A
(ja)
*
|
2004-08-31 |
2006-03-16 |
Konica Minolta Medical & Graphic Inc |
真菌症治療製剤およびその製造方法
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US7786086B2
(en)
*
|
2004-09-08 |
2010-08-31 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
|
EP1793805A1
(en)
*
|
2004-09-09 |
2007-06-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions
|
JP2008512445A
(ja)
*
|
2004-09-09 |
2008-04-24 |
イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム |
炎症状態の治療のためのリポソーム性グルココルチコイドの使用
|
US6998028B1
(en)
*
|
2004-09-24 |
2006-02-14 |
Superpower, Inc. |
Methods for forming superconducting conductors
|
DK1797127T3
(en)
*
|
2004-09-24 |
2017-10-02 |
Amgen Inc |
Modified Fc molecules
|
EP1804824B1
(en)
|
2004-09-29 |
2017-01-04 |
Icahn School of Medicine at Mount Sinai |
Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
|
US20060110387A1
(en)
|
2004-10-05 |
2006-05-25 |
Genentech, Inc. |
Method for treating vasculitis
|
WO2006042112A2
(en)
|
2004-10-05 |
2006-04-20 |
California Institute Of Technology |
Aptamer regulated nucleic acids and uses thereof
|
AU2005295038B2
(en)
|
2004-10-06 |
2012-05-17 |
Mayo Foundation For Medical Education And Research |
B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
|
TW200612993A
(en)
*
|
2004-10-08 |
2006-05-01 |
Alza Corp |
Lipopolymer conjugates
|
US7985417B2
(en)
*
|
2004-10-08 |
2011-07-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Method of lipid structure preparation
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
UA87877C2
(en)
*
|
2004-10-26 |
2009-08-25 |
Фарма Мар С.А., Сосьедад Униперсональ |
Pegylated liposomal doxorubicin in combination with ecteinescidin 743
|
JP2008518951A
(ja)
*
|
2004-10-28 |
2008-06-05 |
アルザ コーポレイション |
凍結乾燥リポソーム配合物及び方法
|
PL1658848T3
(pl)
|
2004-10-29 |
2007-12-31 |
Pharma Mar Sa |
Preparaty zawierające ekteinascydynę i disacharyd
|
EP1807051A2
(en)
|
2004-11-05 |
2007-07-18 |
Inex Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal camptothecin formulations
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
US20060246124A1
(en)
*
|
2004-11-08 |
2006-11-02 |
Pilkiewicz Frank G |
Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
|
WO2006060148A2
(en)
*
|
2004-11-11 |
2006-06-08 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
EP1817004A2
(en)
*
|
2004-11-15 |
2007-08-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combination therapy associating preferably a ceramide with a cytotoxic drug
|
US20060134189A1
(en)
*
|
2004-11-17 |
2006-06-22 |
Protiva Biotherapeutics, Inc |
siRNA silencing of apolipoprotein B
|
US20070298094A1
(en)
*
|
2004-11-18 |
2007-12-27 |
Terumo Kabushiki Kaisha |
Medicinal Composition, Preparation and Combined Preparation
|
CA2590768A1
(en)
*
|
2004-12-14 |
2006-06-22 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of mll-af4 and uses thereof
|
JP2008526883A
(ja)
|
2005-01-07 |
2008-07-24 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
US20080207505A1
(en)
*
|
2005-01-12 |
2008-08-28 |
James Kenneth D |
Bna Conjugates and Methods of Use
|
KR20180080371A
(ko)
|
2005-01-21 |
2018-07-11 |
제넨테크, 인크. |
Her 항체의 고정 용량 투여법
|
JP5221126B2
(ja)
*
|
2005-01-28 |
2013-06-26 |
協和発酵キリン株式会社 |
水溶性物質で表面修飾された微粒子の製造方法
|
EP1853289A4
(en)
|
2005-01-31 |
2008-04-09 |
Vaxinnate Corp |
NOVEL POLYPEPTIDE LIGANDS FOR THE GREAT ARTICLE RECEPTOR 2
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
ES2852549T3
(es)
|
2005-02-09 |
2021-09-13 |
Sarepta Therapeutics Inc |
Composición antisentido para tratamiento de la atrofia muscular
|
EP2548575A1
(en)
|
2005-02-15 |
2013-01-23 |
Duke University |
Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
|
CA2598409A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Icos Corporation |
Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
|
CN101238142B
(zh)
*
|
2005-02-18 |
2012-11-14 |
国立大学法人德岛大学 |
含聚氧化烯链的脂质衍生物及含有该衍生物的脂质膜结构体
|
CA2597717C
(en)
|
2005-02-18 |
2014-10-21 |
Dana-Farber Cancer Institute |
Antibodies against cxcr4 and methods of use thereof
|
SI1850874T1
(sl)
|
2005-02-23 |
2014-01-31 |
Genentech, Inc. |
Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US20060204505A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
JP2006248978A
(ja)
*
|
2005-03-10 |
2006-09-21 |
Mebiopharm Co Ltd |
新規なリポソーム製剤
|
BRPI0607985A2
(pt)
|
2005-03-10 |
2009-10-27 |
Genentech Inc |
modulador da dscr1, métodos de tratamento, método de melhoria de efeitos colaterais e método de inibição do crescimento de tumores
|
EP1861072A2
(en)
*
|
2005-03-14 |
2007-12-05 |
Massachusetts Institute Of Technology |
Nanocells for diagnosis and treatment of diseases and disorders
|
JP2008538351A
(ja)
|
2005-03-21 |
2008-10-23 |
メタボレックス インコーポレーティッド |
癌を含むPPARγ反応性疾患の処置または予防における浮腫を回避するための方法
|
CN1840193B
(zh)
*
|
2005-03-29 |
2010-05-12 |
中国科学院生物物理研究所 |
聚乙二醇化磷脂包载的蒽环类抗肿瘤抗生素的纳米胶束制剂
|
WO2006105361A2
(en)
|
2005-03-31 |
2006-10-05 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
MY148086A
(en)
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
WO2006122079A1
(en)
|
2005-05-06 |
2006-11-16 |
Zymogenetics, Inc. |
Il-31 monoclonal antibodies and methods of use
|
US8124084B2
(en)
|
2005-05-17 |
2012-02-28 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
|
US7919461B2
(en)
*
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
JP2008541781A
(ja)
|
2005-06-06 |
2008-11-27 |
ジェネンテック・インコーポレーテッド |
異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
|
US20070014845A1
(en)
*
|
2005-07-01 |
2007-01-18 |
Yuanpeng Zhang |
Liposomal delivery vehicle for hydrophobic drugs
|
EP2004695A2
(en)
|
2005-07-08 |
2008-12-24 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
AU2006272713A1
(en)
*
|
2005-07-22 |
2007-02-01 |
Y's Therapeutics Co, Ltd. |
Anti-CD26 antibodies and methods of use thereof
|
US8652469B2
(en)
*
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
JP5657862B2
(ja)
*
|
2005-07-28 |
2015-01-21 |
ノバルティス アーゲー |
M−csfに対する抗体の使用
|
US20070055199A1
(en)
|
2005-08-10 |
2007-03-08 |
Gilbert Scott J |
Drug delivery device for buccal and aural applications and other areas of the body difficult to access
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
ZA200800970B
(en)
|
2005-08-15 |
2009-10-28 |
Genentech Inc |
Gene disruptions, compositions and methods relating thereto
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
EP1973928A2
(en)
*
|
2005-10-11 |
2008-10-01 |
Ramot at Tel-Aviv University Ltd. |
Self-assembled fmoc-ff hydrogels
|
TW200732350A
(en)
*
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
US7875602B2
(en)
*
|
2005-10-21 |
2011-01-25 |
Sutter West Bay Hospitals |
Camptothecin derivatives as chemoradiosensitizing agents
|
GB0522082D0
(en)
|
2005-10-31 |
2005-12-07 |
Pharma Mar Sa |
Formulations
|
HUE031122T2
(en)
|
2005-10-31 |
2017-07-28 |
Oncomed Pharm Inc |
Preparations and methods for the treatment of cancer based on human FZD receptors
|
WO2007053696A2
(en)
|
2005-11-01 |
2007-05-10 |
Alnylam Pharmaceuticals, Inc. |
Rnai inhibition of influenza virus replication
|
EP2395012B8
(en)
*
|
2005-11-02 |
2018-06-06 |
Arbutus Biopharma Corporation |
Modified siRNA molecules and uses thereof
|
US7879212B2
(en)
*
|
2005-11-03 |
2011-02-01 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructure-coated electrodes
|
DE102005053066A1
(de)
|
2005-11-04 |
2007-05-10 |
Basf Ag |
Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
|
US20070190182A1
(en)
*
|
2005-11-08 |
2007-08-16 |
Pilkiewicz Frank G |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
WO2007056236A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Transave, Inc. |
Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
|
US20070190180A1
(en)
*
|
2005-11-08 |
2007-08-16 |
Pilkiewicz Frank G |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
|
CA2629299C
(en)
|
2005-11-12 |
2017-08-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Fgf2-related methods for diagnosing and treating depression
|
PL2380592T3
(pl)
|
2005-11-14 |
2018-07-31 |
Teva Pharmaceuticals International Gmbh |
Przeciwciało antagonistyczne skierowane przeciwko peptydowi powiązanemu z genem kalcytoniny
|
AR056806A1
(es)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
Moleculas quimericas de anticuerpo rankl- pth/ pthrp
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
EP1948798B1
(en)
|
2005-11-18 |
2015-04-01 |
Glenmark Pharmaceuticals S.A. |
Anti-alpha2 integrin antibodies and their uses
|
ZA200804162B
(en)
|
2005-11-21 |
2009-12-30 |
Genentech Inc |
Novel gene disruptions, compositions and methods relating thereto
|
CA2630602A1
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
WO2007064658A2
(en)
*
|
2005-11-30 |
2007-06-07 |
Transave, Inc. |
Safe and effective methods of administering therapeutic agents
|
AU2006342792A1
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
|
US8466263B2
(en)
*
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
US20090155345A1
(en)
*
|
2005-12-08 |
2009-06-18 |
Ben Gurion University Of The Negev Research And Development Authority |
Methods for affecting liposome composition ultrasound irradiation
|
US20080300320A1
(en)
*
|
2005-12-09 |
2008-12-04 |
Basf Se |
Use of Polyvinyl Lactam-Polyalkylene Block Copolymers as Solubilisers for Poorly Water-Soluble Compounds
|
WO2007070705A2
(en)
|
2005-12-15 |
2007-06-21 |
The Trustees Of The University Of Pennsylvania |
Cationic lipid-mediated vectors
|
US20090246208A1
(en)
|
2006-01-05 |
2009-10-01 |
Novartis Ag |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
WO2007082154A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
US20100015642A1
(en)
*
|
2006-01-05 |
2010-01-21 |
Kwon Eugene D |
B7-h1 and survivin in cancer
|
AU2007251256B2
(en)
*
|
2006-01-26 |
2013-03-07 |
Recopharma Ab |
Compositions and methods for inhibiting viral adhesion
|
CA2638908C
(en)
|
2006-01-26 |
2021-04-27 |
Susan M. Freier |
Compositions and their uses directed to huntingtin
|
US7829097B2
(en)
*
|
2006-02-06 |
2010-11-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Use of HMGB1 for protection against ischemia reperfusion injury
|
ZA200807714B
(en)
|
2006-02-17 |
2010-01-27 |
Genentech Inc |
Gene disruptions, compositions and methods relating thereto
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US20070218116A1
(en)
*
|
2006-03-14 |
2007-09-20 |
Schwendener Reto A |
Compositions and methods for the treatment of tumors and tumor metastases
|
US9119782B2
(en)
*
|
2006-03-20 |
2015-09-01 |
Mary P. McCourt |
Drug delivery means
|
BRPI0709338A2
(pt)
|
2006-03-21 |
2011-07-12 |
Genentech Inc |
anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf
|
EP2004221A2
(en)
|
2006-03-23 |
2008-12-24 |
Novartis Pharma AG |
Anti-tumor cell antigen antibody therapeutics
|
KR20170061189A
(ko)
|
2006-03-31 |
2017-06-02 |
알닐람 파마슈티칼스 인코포레이티드 |
Eg5 유전자의 발현을 억제하는 이본쇄 리보핵산
|
WO2007126455A2
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
CA2649387A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
EP2881468B1
(en)
|
2006-04-21 |
2017-04-12 |
Intervet International B.V. |
Pestivirus species
|
EP2013222B1
(en)
|
2006-04-28 |
2013-02-13 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
US8298818B2
(en)
*
|
2006-04-28 |
2012-10-30 |
University Of Florida Research Foundation, Inc. |
Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
|
US8697120B2
(en)
*
|
2006-05-01 |
2014-04-15 |
Johns Hopkins University |
Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
|
CA2651031A1
(en)
*
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
US20070264322A1
(en)
*
|
2006-05-10 |
2007-11-15 |
Huang Ken S |
Method for making liposomes conjugated with temperature-sensitive ligands
|
JP2009537147A
(ja)
|
2006-05-15 |
2009-10-29 |
シー レーン バイオテクノロジーズ, エルエルシー |
インフルエンザウイルスに対する中和抗体
|
WO2007133801A2
(en)
*
|
2006-05-15 |
2007-11-22 |
Dmitri B Kirpotin |
Magnetic microparticles comprising organic substances
|
CN101489566B
(zh)
|
2006-05-19 |
2012-04-18 |
阿尔尼拉姆医药品有限公司 |
Aha基因的RNAi调控及其治疗性应用
|
EP2029157A4
(en)
*
|
2006-05-19 |
2009-11-18 |
Georgia Tech Res Inst |
LIGAND OF CARRIERS ABC
|
CA2653451C
(en)
*
|
2006-05-22 |
2015-12-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
EP2023938A4
(en)
*
|
2006-05-23 |
2010-11-10 |
Isis Pharmaceuticals Inc |
MODULATION OF THE EXPRESSION OF ChREBP
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
KR101376634B1
(ko)
|
2006-06-19 |
2014-03-27 |
더 존스 홉킨스 유니버시티 |
리포좀아제에 의한 치료제의 종양특이적 전달
|
US7981425B2
(en)
*
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
ATE540681T1
(de)
|
2006-06-26 |
2012-01-15 |
Amgen Inc |
Verfahren zur behandlung von atherosklerose
|
EP2029173B1
(en)
|
2006-06-26 |
2016-07-20 |
MacroGenics, Inc. |
Fc riib-specific antibodies and methods of use thereof
|
JP5072275B2
(ja)
|
2006-07-03 |
2012-11-14 |
テルモ株式会社 |
閉鎖小胞の分離方法、製剤の製造方法および評価方法
|
AU2007314477B2
(en)
|
2006-07-11 |
2012-03-29 |
Rutgers, The State University Of New Jersey |
MG53 compositions and methods of use
|
US8324158B2
(en)
*
|
2006-07-14 |
2012-12-04 |
Georgia Tech Research Corporation |
Methods for inhibiting CLC-2 channel with GATX2
|
WO2008008523A1
(en)
|
2006-07-14 |
2008-01-17 |
Regents Of The University Of Minnesota |
COMPOUNDS THAT BIND α5β1 INTEGRIN AND METHODS OF USE
|
JP2009543579A
(ja)
|
2006-07-19 |
2009-12-10 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
抗炎症反応のための標的としてのWSX−1/p28
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
JP4936312B2
(ja)
*
|
2006-07-20 |
2012-05-23 |
株式会社島津製作所 |
新規な両親媒性物質、それを用いた薬剤搬送システム及び分子イメージングシステム
|
WO2008013918A2
(en)
*
|
2006-07-26 |
2008-01-31 |
Myelin Repair Foundation, Inc. |
Cell cycle regulation and differentiation
|
CA2659820A1
(en)
|
2006-08-04 |
2008-02-14 |
Novartis Ag |
Ephb3-specific antibody and uses thereof
|
CA2660286A1
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
DK2383297T5
(da)
|
2006-08-14 |
2022-07-04 |
Xencor Inc |
Optimerede antistoffer rettet mod CD19
|
US7867493B2
(en)
|
2006-08-18 |
2011-01-11 |
Novartis Ag |
PRLR-specific antibody and uses thereof
|
EP2061900A2
(en)
|
2006-08-25 |
2009-05-27 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
WO2008027338A2
(en)
|
2006-08-28 |
2008-03-06 |
Kyowa Hakko Kirin Co., Limited |
Antagonistic human light-specific human monoclonal antibodies
|
SG174753A1
(en)
|
2006-08-29 |
2011-10-28 |
Genentech Inc |
Use of tenecteplase for treating acute ischemic stroke
|
RU2009111884A
(ru)
|
2006-09-01 |
2010-10-10 |
Займоджинетикс, Инк. (Us) |
Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
|
CA2600220C
(en)
*
|
2006-09-07 |
2014-12-09 |
Canadian Blood Services |
Surface cross-linked lipidic particles, methods of production and uses therefor
|
ME02371B
(me)
|
2006-09-29 |
2016-06-20 |
Oncomed Pharm Inc |
Sastojci i postupci za dijagnstikovanje i tretman raka
|
EP2099467B1
(en)
|
2006-10-03 |
2017-05-10 |
University Of Medicine And Dentistry Of New Jersey |
Atap peptides, nucleic acids encoding the same and associated methods of use
|
US10925977B2
(en)
*
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
CA2667678A1
(en)
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
CA2667574A1
(en)
*
|
2006-10-27 |
2008-06-12 |
Roger A. Sabbadini |
Compositions and methods for binding sphingosine-1-phosphate
|
AU2007313822A1
(en)
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
WO2008058291A2
(en)
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
AU2007317204A1
(en)
*
|
2006-11-10 |
2008-05-15 |
Dimerix Bioscience Pty Ltd |
Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
|
AU2007323836B2
(en)
|
2006-11-13 |
2013-04-18 |
Icos Corporation |
Thienopyrimidinones for treatment of inflammatory disorders and cancers
|
EP2104513B1
(en)
|
2006-11-27 |
2015-05-20 |
diaDexus, Inc. |
Ovr110 antibody compositions and methods of use
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
EP1932517A3
(en)
*
|
2006-12-11 |
2008-07-16 |
Universiteit Utrecht Holding B.V. |
Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
|
US20100203110A1
(en)
*
|
2006-12-18 |
2010-08-12 |
The Johns Hopkins University |
Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production
|
WO2008079973A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Egfr binding peptides and uses thereof
|
WO2008079976A2
(en)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Dimeric high affinity egfr constructs and uses thereof
|
US8834920B2
(en)
|
2006-12-21 |
2014-09-16 |
Alza Corporation |
Liposome composition for targeting egfr receptor
|
EP2913341A1
(en)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
WO2008083169A2
(en)
*
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
CA2673659A1
(en)
*
|
2006-12-27 |
2008-07-10 |
The Johns Hopkins University |
Methods of detecting and diagnosing inflamatory responses and disorders by determining the level of soluble b7-h4
|
US20090142342A1
(en)
*
|
2006-12-27 |
2009-06-04 |
Johns Hopkins University |
B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
EP2118118B1
(en)
*
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
WO2008091655A2
(en)
*
|
2007-01-23 |
2008-07-31 |
The Regents Of The University Of California |
Methods, compositions and device for directed and controlled heating and release of agents
|
EP2641971A1
(en)
|
2007-01-29 |
2013-09-25 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
WO2008094275A1
(en)
|
2007-01-30 |
2008-08-07 |
New York University |
Peptides for treatment of conditions associated with nitric oxide
|
MX2009008736A
(es)
|
2007-02-22 |
2009-08-24 |
Genentech Inc |
Metodos para detectar la enfermedad inflamatoria intestinal.
|
ES2477497T3
(es)
|
2007-03-02 |
2014-07-17 |
Genentech, Inc. |
Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
|
CA2681302C
(en)
*
|
2007-03-19 |
2013-07-23 |
Dhiraj Khattar |
Proliposomal and liposomal compositions of poorly water-soluble compounds
|
JP4510842B2
(ja)
*
|
2007-03-26 |
2010-07-28 |
キヤノン株式会社 |
ポリヒドロキシアルカノエート被覆リポソーム
|
CA2682161A1
(en)
|
2007-03-29 |
2008-10-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from ebola virus
|
SG194368A1
(en)
|
2007-05-04 |
2013-11-29 |
Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa |
Engineered rabbit antibody variable domains and uses thereof
|
RU2549701C2
(ru)
|
2007-05-07 |
2015-04-27 |
Медиммун, Ллк |
Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
|
WO2008141278A1
(en)
*
|
2007-05-11 |
2008-11-20 |
Centocor, Inc. |
Method for preparing antibody conjugates
|
US20090196913A1
(en)
*
|
2007-05-11 |
2009-08-06 |
Ken Shi Kun Huang |
Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
|
US20090175784A1
(en)
*
|
2007-05-11 |
2009-07-09 |
Joshua Goldstein |
Anti-Alpha V Immunoliposome Composition, Methods, and Uses
|
EP2650018A3
(en)
|
2007-05-14 |
2014-09-03 |
The University of Chicago |
Antibody-LIGHT fusion products for cancer therapeutics
|
EP2173381B1
(en)
|
2007-05-14 |
2013-10-02 |
NovImmune SA |
Fc receptor-binding polypeptides with modified effector functions
|
CA2840407A1
(en)
*
|
2007-05-22 |
2008-12-18 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
WO2008148023A2
(en)
*
|
2007-05-23 |
2008-12-04 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for treating neurological disorders
|
EP3486653A1
(en)
|
2007-05-24 |
2019-05-22 |
The United States Government as represented by The Department of Veterans Affairs |
Treatment of skeletal muscle disorder using ent2
|
JP5989299B2
(ja)
|
2007-05-30 |
2016-09-07 |
エルパス・インコーポレイテッドLpath, Inc. |
リゾホスファチジン酸結合のための組成物と方法
|
EP2708557A1
(en)
|
2007-05-30 |
2014-03-19 |
Xencor, Inc. |
Method and compositions for inhibiting CD32B expressing cells
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
WO2009029342A2
(en)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
B7-dc variants
|
CA2692819A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
SI2176296T1
(sl)
|
2007-07-16 |
2012-05-31 |
Genentech Inc |
Protitelesa proti CD b in imunokonjugati in postopki za uporabo
|
US20090082217A1
(en)
*
|
2007-07-16 |
2009-03-26 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
US8183381B2
(en)
*
|
2007-07-19 |
2012-05-22 |
Metabolex Inc. |
N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
|
JP2010534730A
(ja)
*
|
2007-07-26 |
2010-11-11 |
ビーエーエスエフ ソシエタス・ヨーロピア |
溶液中でのグラフト重合により得られる、ポリエーテルに基づく固体形態のコポリマーの調製方法
|
EP2522721B1
(en)
|
2007-07-26 |
2016-05-04 |
Amgen, Inc |
Modified lecithin-cholesterol acyltransferase enzymes
|
US7666973B2
(en)
|
2007-07-30 |
2010-02-23 |
Tyco Healthcare Group Lp |
Carbonate copolymers
|
CA2693208A1
(en)
|
2007-08-02 |
2009-02-05 |
Victoria Smith |
Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
|
WO2009020093A1
(ja)
*
|
2007-08-09 |
2009-02-12 |
Daiichi Sankyo Company, Limited |
デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
|
US20090048423A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Tyco Healthcare Group Lp |
Phospholipid Copolymers
|
US8268958B2
(en)
|
2007-08-15 |
2012-09-18 |
Tyco Healthcare Group Ip |
Phospholipid copolymers
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
JP2010539089A
(ja)
*
|
2007-09-07 |
2010-12-16 |
ゲンシア コーポレーション |
ミトコンドリア組成物及びその使用
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
US20110014118A1
(en)
*
|
2007-09-21 |
2011-01-20 |
Lawrence Tamarkin |
Nanotherapeutic colloidal metal compositions and methods
|
CA2700378A1
(en)
*
|
2007-09-21 |
2009-03-29 |
Cytimmune Sciences, Inc. |
Nanotherapeutic colloidal metal compositions and methods
|
CN106310293A
(zh)
|
2007-09-27 |
2017-01-11 |
免疫疫苗技术有限公司 |
在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
|
CA2700810A1
(en)
|
2007-09-28 |
2009-04-02 |
Universitatsspital Basel |
Immunoliposomes for treatment of cancer
|
EP2205741A2
(en)
|
2007-10-02 |
2010-07-14 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
UA114700C2
(uk)
*
|
2007-10-16 |
2017-07-25 |
Біокон Лімітед |
Тверда фармацевтична форма для перорального застосування та процес її виготовлення
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
AU2008324068A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
AU2008324800B2
(en)
|
2007-11-05 |
2014-03-27 |
Astrazeneca Ab |
Methods of treating scleroderma
|
DK2514436T3
(en)
|
2007-11-07 |
2018-03-12 |
Genentech Inc |
IL-22 FOR USE IN TREATMENT OF MICROBIAL DISEASES
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
MX2010005244A
(es)
*
|
2007-11-12 |
2010-10-25 |
Theraclone Sciences Inc |
Composiciones y métodos para la terapia y el diagnóstico de influenza.
|
US8598165B2
(en)
|
2007-11-26 |
2013-12-03 |
University Of Kansas |
Morpholines as selective inhibitors of cytochrome P450 2A13
|
CA2708221C
(en)
|
2007-12-06 |
2017-07-25 |
Wayne A. Marasco |
Antibodies against influenza virus and methods of use thereof
|
KR101603109B1
(ko)
|
2007-12-07 |
2016-03-25 |
지모제넥틱스, 인코포레이티드 |
Il-31에 특이적인 인간화된 항체 분자
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
EP2617828B1
(en)
|
2007-12-10 |
2014-09-24 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
KR101499278B1
(ko)
|
2007-12-17 |
2015-03-06 |
화이자 리미티드 |
간질성 방광염의 치료
|
US8962806B2
(en)
|
2007-12-28 |
2015-02-24 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
EP2224912B1
(en)
|
2008-01-02 |
2016-05-11 |
TEKMIRA Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
US20090181094A1
(en)
*
|
2008-01-15 |
2009-07-16 |
Eric Yueh-Lang Sheu |
Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents
|
AR070141A1
(es)
*
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
SI2247620T1
(sl)
|
2008-01-31 |
2016-09-30 |
Genentech, Inc. |
Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
|
US20110020325A1
(en)
*
|
2008-02-29 |
2011-01-27 |
Kwon Eugene D |
Methods for reducing granulomatous inflammation
|
KR101397407B1
(ko)
|
2008-03-05 |
2014-06-19 |
알닐람 파마슈티칼스 인코포레이티드 |
Eg5 및 VEGF 유전자의 발현을 억제하기 위한 조성물 및 방법
|
JP5544309B2
(ja)
|
2008-03-10 |
2014-07-09 |
セラクローン サイエンシーズ, インコーポレイテッド |
サイトメガロウイルス感染の治療および診断のための組成物および方法
|
EP2105145A1
(en)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Method for muscle-specific delivery lipid-conjugated oligonucleotides
|
AU2009228058A1
(en)
|
2008-03-28 |
2009-10-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to viral antigens
|
US20090270404A1
(en)
*
|
2008-03-31 |
2009-10-29 |
Metabolex, Inc. |
Oxymethylene aryl compounds and uses thereof
|
BRPI0911332A2
(pt)
|
2008-04-04 |
2019-09-24 |
Calando Pharmaceuticals Inc |
composições e uso de inibidores de epas1
|
BRPI0906550B8
(pt)
|
2008-04-09 |
2022-01-11 |
Genentech Inc |
Anticorpo anti-tigit, usos de um anticorpo anti-tigit e métodos in vitro para estimular a interação de cd226-pvr e/ou a interação de cd96-pvr, para aumentar ou estimular a proliferação de uma célula t ou a liberação de citocinas proinflamatórias por uma célula dendrítica, para aumentar ou estimular a resposta imune de célula t e para aumentar ou estimular a produção de citocinas proinflamatórias por uma célula dendrítica
|
EP3023502A1
(en)
|
2008-04-10 |
2016-05-25 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
PT2279254T
(pt)
|
2008-04-15 |
2017-09-04 |
Protiva Biotherapeutics Inc |
Novas formulações lipídicas para entrega de ácido nucleico
|
CA2722668A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Wyeth Llc |
Methods for treating inflammation
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
WO2009136297A2
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting toxin a from clostridium difficile
|
US20090280104A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting shiga toxin and shiga-like toxin
|
MX2010012368A
(es)
|
2008-05-16 |
2010-12-06 |
Genentech Inc |
Uso de biomarcadores para evaluar un tratamiento contra trastornos inflamatorios gastrointestinales con antagonistas de beta7-integrina.
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
WO2009140853A1
(en)
*
|
2008-05-23 |
2009-11-26 |
The University Of Hong Kong |
Combination therapy for the treatment of influenza
|
CA2723918C
(en)
|
2008-06-05 |
2018-01-09 |
Immunovaccine Technologies Inc. |
Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
|
WO2009148121A1
(ja)
|
2008-06-05 |
2009-12-10 |
株式会社 島津製作所 |
新規な分子集合体、それを用いた分子イメージング用分子プローブ及び薬剤搬送システム用分子プローブ、並びに分子イメージングシステム及び薬剤搬送システム
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
US20110104074A1
(en)
*
|
2008-06-18 |
2011-05-05 |
University Of Louisville Research Foundation, Inc. |
Methods for targeted cancer treatment and detection
|
US20100003315A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Willeford Kenneth L |
Method and Composition for the Treatment of Skin Conditions
|
RS53924B1
(en)
|
2008-07-08 |
2015-08-31 |
Oncomed Pharmaceuticals, Inc. |
NOTCH-BINDING AGENTS AND ANTAGONISTS AND PROCEDURES FOR THEIR USE
|
EP2310440A4
(en)
*
|
2008-07-10 |
2013-06-05 |
Serina Therapeutics Inc |
POLYOXAZOLINES WITH INTERNAL END GROUPS, POLYOXAZOLINES MANUFACTURED FROM PROTECTED INITIAL GROUPS AND CORRESPONDING COMPOUNDS
|
US20100008900A1
(en)
*
|
2008-07-14 |
2010-01-14 |
The University Of Hong Kong |
Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
US20110237646A1
(en)
*
|
2008-08-07 |
2011-09-29 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression for the treatment of cns related disorders
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
CA2734225A1
(en)
|
2008-08-15 |
2010-02-18 |
Georgetown University |
Fluorescent regulators of rassf1a expression and human cancer cell proliferation
|
EP2331092B1
(en)
|
2008-08-21 |
2014-03-19 |
The Johns Hopkins University |
Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
|
MX2011001135A
(es)
|
2008-08-22 |
2011-03-21 |
Sanofi Aventis |
[4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-m etoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos.
|
EP3301116A1
(en)
|
2008-08-25 |
2018-04-04 |
Dana Farber Cancer Institute, Inc. |
Conserved influenza hemagglutinin epitope and antibodies thereto
|
US8252762B2
(en)
|
2008-08-25 |
2012-08-28 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
KR20110050529A
(ko)
|
2008-08-25 |
2011-05-13 |
앰플리뮨, 인크. |
Pd-1 길항제의 조성물 및 사용 방법
|
EA201170375A1
(ru)
*
|
2008-08-25 |
2012-03-30 |
Эмплиммьюн, Инк. |
Антагонисты pd-1 и способы их применения
|
EP2331690B1
(en)
|
2008-09-02 |
2016-01-13 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of mutant egfr gene
|
RU2530583C2
(ru)
|
2008-09-10 |
2014-10-10 |
Дженентек, Инк. |
Способы ингибирования глазного ангиогенеза
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9拮抗劑類
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
AU2009293658A1
(en)
|
2008-09-22 |
2010-03-25 |
James Cardia |
Reduced size self-delivering RNAi compounds
|
EP3109321B1
(en)
|
2008-09-25 |
2019-05-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
BRPI0920552A2
(pt)
|
2008-10-09 |
2019-09-24 |
Univ Northeastern |
nanosistemas poliméricos auto-organizáveis multifuncionais
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
IL281434B2
(en)
|
2008-10-20 |
2023-09-01 |
Alnylam Pharmaceuticals Inc |
Compounds and methods for inhibiting transthyretin expression
|
US8147847B2
(en)
*
|
2008-10-21 |
2012-04-03 |
International Vaccine Institute |
Shigella protein antigens and methods
|
WO2010048207A2
(en)
*
|
2008-10-21 |
2010-04-29 |
Metabolex, Inc. |
Aryl gpr120 receptor agonists and uses thereof
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
CA2742899A1
(en)
*
|
2008-11-06 |
2010-05-14 |
Glenmark Pharmaceuticals, S.A. |
Treatment with anti-alpha2 integrin antibodies
|
WO2010054401A1
(en)
|
2008-11-10 |
2010-05-14 |
Alnylam Pharmaceuticals, Inc. |
Novel lipids and compositions for the delivery of therapeutics
|
ES2674719T3
(es)
|
2008-11-13 |
2018-07-03 |
Gilead Calistoga Llc |
Terapias para neoplasias hematológicas
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
SI2752189T1
(sl)
|
2008-11-22 |
2017-02-28 |
F. Hoffmann-La Roche Ag |
Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka
|
WO2010068414A2
(en)
*
|
2008-11-25 |
2010-06-17 |
Bowen Richard L |
Methods for treating obesity related disease
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
KR101749352B1
(ko)
|
2008-12-04 |
2017-06-20 |
큐알엔에이, 인크. |
Sirt1에 대한 천연 안티센스 전사체의 억제에 의해 sirt1 관련된 질환의 치료
|
ES2637063T3
(es)
|
2008-12-04 |
2017-10-10 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con genes supresores de tumor mediante inhibición del transcrito antisentido natural al gen
|
CA2745329C
(en)
|
2008-12-04 |
2022-07-12 |
Opko Curna, Llc |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
US8628762B2
(en)
|
2008-12-10 |
2014-01-14 |
Icahn School Of Medicine At Mount Sinai |
T-helper cell type 17 lineage-specific adjuvants, compositions and methods
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
AR074760A1
(es)
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
|
AR074776A1
(es)
|
2008-12-18 |
2011-02-09 |
Sanofi Aventis |
Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
AU2009331490C1
(en)
|
2008-12-22 |
2013-11-28 |
Creabilis S.A. |
Synthesis of polymer conjugates of indolocarbazole compounds
|
PT2376088T
(pt)
|
2008-12-23 |
2017-05-02 |
Gilead Pharmasset Llc |
Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
|
BRPI0923815A2
(pt)
|
2008-12-23 |
2015-07-14 |
Pharmasset Inc |
Síntese de nucleosídeos de purina
|
NZ593649A
(en)
|
2008-12-23 |
2013-11-29 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
JP6066035B2
(ja)
|
2009-02-12 |
2017-01-25 |
クルナ・インコーポレーテッド |
グリア細胞由来神経栄養因子(gdnf)関連疾病の、gdnfに対する天然アンチセンス転写物の抑制による治療
|
PL2396038T3
(pl)
|
2009-02-12 |
2016-05-31 |
Curna Inc |
Leczenie chorób związanych z neurotropowym czynnikiem pochodzenia mózgowego (bdnf) poprzez zahamowanie naturalnego antysensownego transkryptu bdnf
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
US8975389B2
(en)
|
2009-03-02 |
2015-03-10 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
JP6250263B2
(ja)
|
2009-03-04 |
2017-12-20 |
クルナ・インコーポレーテッド |
サーチュイン1(sirt1)に対する天然アンチセンス転写物の抑制によるsirt1関連疾患の治療
|
EP2228059A1
(en)
|
2009-03-12 |
2010-09-15 |
Universitätsspital Basel |
Chemotherapeutic composition for the treatment of cancer
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
MX2011009751A
(es)
|
2009-03-16 |
2011-09-29 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
WO2010107740A2
(en)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
NZ595307A
(en)
|
2009-03-24 |
2013-11-29 |
Gilead Calistoga Llc |
Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
|
DK2411411T3
(en)
|
2009-03-25 |
2016-11-07 |
Hoffmann La Roche |
New anti-alpha5beta1 antibodies and uses thereof
|
JP6132548B2
(ja)
|
2009-04-01 |
2017-05-24 |
ジェネンテック, インコーポレイテッド |
抗FcRH5抗体および免疫接合体および使用方法
|
UA105384C2
(ru)
|
2009-04-01 |
2014-05-12 |
Дженентек, Инк. |
Лечение нарушений, связанных с инсулинорезистентностью
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
JP2012524126A
(ja)
*
|
2009-04-20 |
2012-10-11 |
ギリアド カリストガ リミテッド ライアビリティ カンパニー |
固形腫瘍の治療方法
|
EP3524275A1
(en)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Innate immune supression enables repeated delivery of long rna molecules
|
US8609101B2
(en)
|
2009-04-23 |
2013-12-17 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
|
AU2010245011B2
(en)
*
|
2009-04-27 |
2015-09-03 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
EP2248903A1
(en)
|
2009-04-29 |
2010-11-10 |
Universitat Autònoma De Barcelona |
Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
|
US8524784B2
(en)
|
2009-04-30 |
2013-09-03 |
Intezyne Technologies, Incorporated |
Polymer micelles containing anthracylines for the treatment of cancer
|
EP2424359A4
(en)
|
2009-04-30 |
2014-01-15 |
Intezyne Technologies Inc |
POLYMIC MICELLES WITH ANTHRACYCLINES FOR THE TREATMENT OF CANCER
|
CN102639151B
(zh)
|
2009-05-01 |
2017-03-22 |
库尔纳公司 |
通过针对hbf/hbg的天然反义转录物的抑制治疗血红蛋白(hbf/hbg)相关疾病
|
JP5889783B2
(ja)
|
2009-05-05 |
2016-03-22 |
テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation |
免疫細胞へオリゴヌクレオチドを送達する方法
|
NZ596186A
(en)
|
2009-05-05 |
2014-03-28 |
Alnylam Pharmaceuticals Inc |
Lipid compositions
|
MX348013B
(es)
|
2009-05-05 |
2017-05-23 |
Novimmune Sa |
Anticuerpos anti il-17f y metodos de uso de los mismos.
|
CA2761142C
(en)
|
2009-05-06 |
2021-06-08 |
Opko Curna, Llc |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
US9155754B2
(en)
|
2009-05-06 |
2015-10-13 |
Curna, Inc. |
Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
|
ES2664590T3
(es)
|
2009-05-18 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con factores de reprogramación por inhibición del tránscrito antisentido natural a un factor de reprogramación
|
EP2432499A2
(en)
|
2009-05-20 |
2012-03-28 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
CA2762302A1
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
CN102549158B
(zh)
|
2009-05-22 |
2017-09-26 |
库尔纳公司 |
通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
|
US8791085B2
(en)
|
2009-05-28 |
2014-07-29 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
TR201811076T4
(tr)
|
2009-06-10 |
2018-08-27 |
Arbutus Biopharma Corp |
Geliştirilmiş lipit formulasyonu.
|
WO2010143193A1
(en)
|
2009-06-11 |
2010-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Targeted liposomes comprising n-containing bisphosphonates and uses thereof
|
US8951981B2
(en)
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
US20120171170A1
(en)
|
2009-06-16 |
2012-07-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
WO2010151671A2
(en)
|
2009-06-24 |
2010-12-29 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
US8921330B2
(en)
|
2009-06-26 |
2014-12-30 |
Curna, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
WO2010151808A1
(en)
|
2009-06-26 |
2010-12-29 |
Sea Lane Biotechnologies, Llc |
Expression of surrogate light chains
|
EP2450055B1
(en)
|
2009-06-30 |
2018-01-03 |
Obshestvo S OgranichennoyOtvetstvennostiu"OncoMax" |
Method for suppressing renal tumor growth by blocking fibroblast growth factor receptor
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
KR20120051002A
(ko)
|
2009-07-07 |
2012-05-21 |
제넨테크, 인크. |
자가면역 탈수초성 질환의 진단 및 치료
|
CA2768444A1
(en)
*
|
2009-07-17 |
2011-01-20 |
Rigshospitalet |
Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
|
EA201270184A1
(ru)
|
2009-07-21 |
2012-08-30 |
ГИЛИЭД КАЛИСТОГА ЭлЭлСи |
Лечение расстройств печени ингибиторами pi3k
|
US9937128B2
(en)
|
2009-08-03 |
2018-04-10 |
The University Of North Carolina At Chapel Hill |
Liposomes comprising a calcium phosphate-containing precipitate
|
EP2462229B1
(en)
|
2009-08-05 |
2016-05-11 |
CuRNA, Inc. |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
AP3574A
(en)
|
2009-08-14 |
2016-02-08 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
TWI451875B
(zh)
|
2009-08-15 |
2014-09-11 |
建南德克公司 |
用於治療先前治療過之乳癌之抗-血管新生療法
|
FR2955324A1
(fr)
|
2010-01-15 |
2011-07-22 |
Sanofi Aventis |
[4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
US9011853B2
(en)
|
2009-08-31 |
2015-04-21 |
Amplimmune, Inc. |
B7-H4 fusion proteins and methods of use thereof
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
EP2473522B1
(en)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN102666553B
(zh)
|
2009-10-01 |
2015-05-06 |
赛马拜制药公司 |
取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
|
US20130079382A1
(en)
|
2009-10-12 |
2013-03-28 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
MX368790B
(es)
*
|
2009-10-15 |
2019-10-16 |
Genentech Inc |
Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
|
EP3485908B1
(en)
|
2009-10-16 |
2021-08-18 |
Mereo BioPharma 5, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
ES2564207T3
(es)
|
2009-10-22 |
2016-03-18 |
F. Hoffmann-La Roche Ag |
Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos
|
WO2011053468A1
(en)
|
2009-10-30 |
2011-05-05 |
Sanofi-Aventis |
Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
|
CN105801550B
(zh)
|
2009-11-05 |
2019-06-14 |
理森制药股份公司 |
新型苯并吡喃激酶调节剂
|
WO2011056234A1
(en)
|
2009-11-06 |
2011-05-12 |
Fibrogen, Inc. |
Treatment for radiation-induced disorders
|
EP3037435B1
(en)
|
2009-11-17 |
2019-08-07 |
MUSC Foundation for Research Development |
Human monoclonal antibodies to human nucleolin
|
EP2507264A2
(en)
|
2009-11-30 |
2012-10-10 |
F. Hoffmann-La Roche AG |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid 2)
|
EP3296398A1
(en)
|
2009-12-07 |
2018-03-21 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
EP2509997B1
(en)
|
2009-12-07 |
2017-08-30 |
i2 Pharmaceuticals, Inc. |
Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
|
JP2013513588A
(ja)
|
2009-12-11 |
2013-04-22 |
ジーンコード エーエス |
Gdnfファミリーリガンド(gfl)のミメティックまたはretシグナル経路活性化因子を用いた、神経系細胞の生存を容易にするための方法
|
US20130004490A1
(en)
|
2009-12-14 |
2013-01-03 |
The United States of America, as represented by the Secretary, Department |
Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease
|
US9173895B2
(en)
|
2009-12-16 |
2015-11-03 |
Curna, Inc. |
Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
WO2011075656A1
(en)
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
CA2782375C
(en)
|
2009-12-23 |
2023-10-31 |
Opko Curna, Llc |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
DK2516468T3
(en)
|
2009-12-23 |
2016-05-23 |
Synimmune Gmbh |
ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
|
KR101891352B1
(ko)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
간세포 성장 인자(hgf)에 대한 천연 안티센스 전사체의 억제에 의한 hgf 관련 질환의 치료
|
SG181501A1
(en)
|
2009-12-23 |
2012-07-30 |
Sanofi Sa |
Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
|
MX2012007080A
(es)
|
2009-12-23 |
2012-07-20 |
Sanofi Sa |
[4[4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(1h-pirrolo-pi ri-din-il)-metanonas y sintesis de las mismas.
|
DK2519542T3
(en)
|
2009-12-28 |
2019-01-14 |
Onco Therapy Science Inc |
ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
|
RU2611186C2
(ru)
|
2009-12-29 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63
|
ES2657452T3
(es)
|
2009-12-29 |
2018-03-05 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor respiratorio nuclear 1 (NRF1) mediante inhibición de transcrito antisentido natural a NRF1
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
JP5886757B2
(ja)
|
2010-01-04 |
2016-03-16 |
カッパーアールエヌエー,インコーポレイテッド |
インターフェロン調節因子8(irf8)に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子8(irf8)関連疾患の治療
|
CN102822342B
(zh)
|
2010-01-06 |
2017-05-10 |
库尔纳公司 |
通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
|
WO2011083845A1
(ja)
*
|
2010-01-08 |
2011-07-14 |
富士フイルム株式会社 |
腫瘍部位に対する標的化剤
|
CA2786535C
(en)
|
2010-01-11 |
2019-03-26 |
Curna, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
WO2011088215A2
(en)
|
2010-01-13 |
2011-07-21 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
WO2011090971A2
(en)
|
2010-01-19 |
2011-07-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
NO2529015T3
(nl)
|
2010-01-25 |
2018-04-14 |
|
|
US8198337B2
(en)
*
|
2010-01-27 |
2012-06-12 |
Momentive Performance Materials Inc. |
Demulsifier compositions and methods for separating emulsions using the same
|
EP2531175A2
(en)
|
2010-02-01 |
2012-12-12 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
Liposomes comprising amphipathic drugs and method for their preparation
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
TWI457135B
(zh)
|
2010-02-23 |
2014-10-21 |
Genentech Inc |
治療鉑敏感性復發性晚期上皮卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、吉西他濱與抗vegf抗體之組合
|
US8877897B2
(en)
|
2010-02-23 |
2014-11-04 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
RU2545401C2
(ru)
|
2010-02-23 |
2015-03-27 |
Санофи |
Антитела к интегрину альфа-2 и их применения
|
US8298535B2
(en)
|
2010-02-24 |
2012-10-30 |
Rinat Neuroscience Corp. |
Anti-IL-7 receptor antibodies
|
EP2538929A4
(en)
|
2010-02-25 |
2014-07-09 |
Univ Johns Hopkins |
PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
|
SG183867A1
(en)
|
2010-03-11 |
2012-10-30 |
Rinat Neuroscience Corp |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
SI2550018T1
(sl)
|
2010-03-22 |
2019-05-31 |
F. Hoffmann-La Roche Ag |
Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine
|
EP2550000A4
(en)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
RNAI COMPOUNDS OF REDUCED SIZE ADMINISTERING
|
ES2625406T3
(es)
|
2010-03-25 |
2017-07-19 |
Oregon Health & Science University |
Glicoproteínas de CMV y vectores recombinantes
|
EP3329924B1
(en)
|
2010-03-29 |
2021-05-05 |
Alnylam Pharmaceuticals, Inc. |
Dsrna therapy for transthyretin (ttr) related ocular amyloidosis
|
CN102971340A
(zh)
|
2010-03-29 |
2013-03-13 |
酵活有限公司 |
具有增强的或抑制的效应子功能的抗体
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
KR101760242B1
(ko)
|
2010-03-31 |
2017-07-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
항-cd40 항체
|
EP2609923B1
(en)
|
2010-03-31 |
2017-05-24 |
Gilead Pharmasset LLC |
Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
|
DK2552930T3
(en)
|
2010-03-31 |
2015-12-07 |
Gilead Pharmasset Llc |
Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-DIHYDROPYRIMIDIN- 1- (2 H) -yl) - 4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
WO2011125015A2
(en)
|
2010-04-05 |
2011-10-13 |
Bar-Ilan University |
Protease-activatable pore-forming polypeptides
|
JP2013523162A
(ja)
|
2010-04-06 |
2013-06-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Cd274/pd−l1遺伝子の発現を阻害するための組成物および方法
|
CN102858979B
(zh)
|
2010-04-09 |
2018-01-26 |
库尔纳公司 |
通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
WO2011133868A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
US9096660B2
(en)
|
2010-04-26 |
2015-08-04 |
Abraxis Bioscience, Llc |
SPARC binding antibodies and uses thereof
|
WO2011135905A1
(ja)
*
|
2010-04-28 |
2011-11-03 |
国立大学法人北海道大学 |
脂質膜構造体
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
US20110294868A1
(en)
|
2010-04-29 |
2011-12-01 |
Monia Brett P |
Modulation of transthyretin expression
|
ES2552954T3
(es)
|
2010-04-30 |
2015-12-03 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
CN102933711B
(zh)
|
2010-05-03 |
2018-01-02 |
库尔纳公司 |
通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病
|
WO2011139985A1
(en)
|
2010-05-03 |
2011-11-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
DK2569430T3
(en)
|
2010-05-12 |
2019-02-04 |
Univ Columbia |
PROCEDURES FOR MANUFACTURING ENTEROENDOCRIN CELLS WHICH MANUFACTURE AND SECRET INSULIN
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
DK2571878T3
(en)
|
2010-05-17 |
2019-02-11 |
Indian Incozen Therapeutics Pvt Ltd |
Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
|
WO2011146574A1
(en)
|
2010-05-18 |
2011-11-24 |
Neumedicines, Inc. |
Il-12 formulations for enhancing hematopoiesis
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
EP3957653A1
(en)
|
2010-06-02 |
2022-02-23 |
Dana Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
DK2575764T3
(en)
|
2010-06-03 |
2017-08-07 |
Alnylam Pharmaceuticals Inc |
BIODEGRADABLE LIPIDS FOR THE ACTIVATION OF ACTIVE AGENTS
|
CA2801182A1
(en)
|
2010-06-16 |
2011-12-22 |
Metabolex, Inc. |
Gpr120 receptor agonists and uses thereof
|
US8299117B2
(en)
|
2010-06-16 |
2012-10-30 |
Metabolex Inc. |
GPR120 receptor agonists and uses thereof
|
CN103153283B
(zh)
|
2010-06-19 |
2017-05-17 |
健康科学西部大学 |
Peg化脂质体包封的糖肽抗生素的新制剂
|
CN103037843A
(zh)
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
|
AU2011270828B2
(en)
|
2010-06-24 |
2015-09-24 |
Genentech, Inc. |
Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
|
CN102309448B
(zh)
*
|
2010-06-29 |
2014-07-09 |
中国人民解放军军事医学科学院毒物药物研究所 |
一种肺部给药的环丙沙星药用组合物及其制备方法
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
AU2011276234B2
(en)
|
2010-07-06 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Liposomes with lipids having an advantageous pKa- value for RNA delivery
|
PL2591114T3
(pl)
|
2010-07-06 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Immunizacja dużych ssaków małymi dawkami rna
|
WO2012006377A2
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Delivery of rna to trigger multiple immune pathways
|
HRP20221522T1
(hr)
|
2010-07-06 |
2023-02-17 |
Glaxosmithkline Biologicals S.A. |
Čestice za dostavljanje nalik virionu za samo-replicirajuće rna molekule
|
KR20130050966A
(ko)
|
2010-07-12 |
2013-05-16 |
씨오브이엑스 테크놀로지스 아일랜드 리미티드 |
다기능적 항체 접합체
|
EP2593547B1
(en)
|
2010-07-14 |
2017-11-15 |
CuRNA, Inc. |
Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
|
EP3696195B1
(en)
|
2010-07-23 |
2024-02-14 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US8906943B2
(en)
|
2010-08-05 |
2014-12-09 |
John R. Cashman |
Synthetic compounds and methods to decrease nicotine self-administration
|
AU2011289275A1
(en)
|
2010-08-12 |
2013-02-21 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
EP3970742B1
(en)
*
|
2010-08-31 |
2022-05-25 |
GlaxoSmithKline Biologicals S.A. |
Pegylated liposomes for delivery of immunogen-encoding rna
|
EP3556396B1
(en)
|
2010-08-31 |
2022-04-20 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
ES2935542T3
(es)
|
2010-08-31 |
2023-03-07 |
Glaxosmithkline Biologicals Sa |
Liposomas pequeños para la administración de ARN que codifica para inmunógeno
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
ES2640755T3
(es)
|
2010-10-06 |
2017-11-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
|
EP3520813B1
(en)
|
2010-10-11 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Antigen delivery platforms
|
RU2597972C2
(ru)
|
2010-10-22 |
2016-09-20 |
Курна Инк. |
Лечение заболеваний, связанных с геном альфа-l-идуронидазы (idua), путем ингибирования природного антисмыслового транскрипта гена idua
|
US20120201821A1
(en)
|
2010-10-25 |
2012-08-09 |
Gonzalez Jr Lino |
Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
|
DK2633052T3
(en)
|
2010-10-27 |
2018-07-16 |
Curna Inc |
TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
|
CA3017116A1
(en)
|
2010-11-04 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Anti-il-23 antibodies
|
WO2012061811A2
(en)
|
2010-11-05 |
2012-05-10 |
Fibrogen, Inc. |
Treatment method for lung remodeling diseases
|
US9339513B2
(en)
|
2010-11-09 |
2016-05-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
WO2012065044A2
(en)
|
2010-11-12 |
2012-05-18 |
Purdue Research Foundation |
Treating bladder tumor cells using fibronectin attachment protein as a target
|
EP2640831A1
(en)
|
2010-11-17 |
2013-09-25 |
Sea Lane Biotechnologies,llc. |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
EP2640359A4
(en)
|
2010-11-18 |
2015-11-04 |
Gen Hospital Corp |
NEW COMPOSITIONS AND USES OF BLOOD PRESSURE RECIPROCATORS FOR CANCER THERAPY
|
EP2643463B1
(en)
|
2010-11-23 |
2017-09-27 |
CuRNA, Inc. |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
US8841275B2
(en)
|
2010-11-30 |
2014-09-23 |
Gilead Pharmasset Llc |
2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHOD FOR INCREASING AN ERYTHROPOIETIN (EPO) PREPARATION
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
KR20140092226A
(ko)
|
2010-12-14 |
2014-07-23 |
테크니칼 유니버시티 오브 덴마크 |
나노입자 조성물에서 방사성 핵종의 포집
|
EP2468259A1
(en)
*
|
2010-12-23 |
2012-06-27 |
Traslational Cancer Drugs Pharma, S.L. |
Pharmaceutical compositions of pyridinium and quinolinium derivatives
|
CA2834968C
(en)
|
2011-01-05 |
2018-01-09 |
Livon Laboratories |
Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
|
CA2821985C
(en)
|
2011-01-11 |
2019-07-09 |
Dimerix Bioscience Pty Ltd |
Combination therapy
|
CA2824526C
(en)
|
2011-01-11 |
2020-07-07 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
MX365647B
(es)
|
2011-02-02 |
2019-06-10 |
Excaliard Pharmaceuticals Inc |
El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
|
RU2440142C1
(ru)
|
2011-02-07 |
2012-01-20 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
MX2013009357A
(es)
|
2011-02-14 |
2014-02-17 |
Theraclone Sciences Inc |
Composiciones y metodos para la terapia y diagnostico de la influenza.
|
PL226015B1
(pl)
*
|
2011-03-03 |
2017-06-30 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną |
Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
|
US9920110B2
(en)
|
2011-03-09 |
2018-03-20 |
Cell Signaling Technology, Inc. |
Methods and reagents for creating monoclonal antibodies
|
JP2014509591A
(ja)
|
2011-03-15 |
2014-04-21 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
SG193434A1
(en)
|
2011-03-16 |
2013-10-30 |
Amgen Inc |
Potent and selective inhibitors of nav1.3 and nav1.7
|
US10184942B2
(en)
|
2011-03-17 |
2019-01-22 |
University Of South Florida |
Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
|
WO2012134975A1
(en)
|
2011-03-28 |
2012-10-04 |
St. Jude Children's Research Hospital |
Methods and compositions employing immunogenic fusion proteins
|
MX343008B
(es)
|
2011-03-29 |
2016-10-21 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
|
CN114642731A
(zh)
|
2011-03-31 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
施用β7整联蛋白拮抗剂的方法
|
EP2508176A1
(en)
|
2011-04-08 |
2012-10-10 |
Lipotarg Gmbh |
Novel combination treatment of cancer
|
CA2832972C
(en)
|
2011-04-13 |
2019-04-30 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
KR101589135B1
(ko)
|
2011-04-20 |
2016-01-29 |
주식회사 셀앤바이오 |
인간화 항-emapii 항체 및 이의 용도
|
PT2699264T
(pt)
|
2011-04-20 |
2018-05-23 |
Medimmune Llc |
Anticorpos e outras moléculas que ligam b7-h1 e pd-1
|
JP6118314B2
(ja)
|
2011-05-04 |
2017-04-19 |
ライゼン・ファーマシューティカルズ・エスアー |
タンパク質キナーゼのモジュレーターとしての新規化合物
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
JP6662566B2
(ja)
|
2011-06-02 |
2020-03-11 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
エキソビボ組織培養システムのための方法および使用
|
KR102043422B1
(ko)
|
2011-06-09 |
2019-11-11 |
큐알엔에이, 인크. |
프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료
|
HUE037408T2
(hu)
|
2011-06-10 |
2018-08-28 |
Univ Oregon Health & Science |
CMV glikoproteinek és rekombináns vektorok
|
CN103597074A
(zh)
|
2011-06-16 |
2014-02-19 |
Isis制药公司 |
成纤维细胞生长因子受体4表达的反义调节
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
US20140275211A1
(en)
|
2011-06-21 |
2014-09-18 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
KR20230084331A
(ko)
|
2011-06-21 |
2023-06-12 |
알닐람 파마슈티칼스 인코포레이티드 |
아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
|
EP2537532A1
(en)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
|
EP3597750B1
(en)
|
2011-06-23 |
2022-05-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
WO2013003112A1
(en)
|
2011-06-27 |
2013-01-03 |
The Jackson Laboratory |
Methods and compositions for treatment of cancer and autoimmune disease
|
WO2013003647A2
(en)
|
2011-06-28 |
2013-01-03 |
Sea Lane Biotechnologies, Llc |
Multispecific stacked variable domain binding proteins
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
LT2731591T
(lt)
|
2011-07-13 |
2020-12-28 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Liposomos, kuriose kartu inkapsuliuotas bisfosfonatas ir amfipatinis agentas
|
EP2731623A1
(en)
|
2011-07-14 |
2014-05-21 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
WO2013019857A2
(en)
|
2011-08-01 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
WO2013025779A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
FR2979239A1
(fr)
*
|
2011-08-25 |
2013-03-01 |
Trophos |
Liposome comprenant au moins un derive de cholesterol
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
US9399791B2
(en)
|
2011-08-31 |
2016-07-26 |
St. Jude Children's Research Hospital |
Methods of treating alzheimer's disease by administration of protective protein/cathepsin A
|
AU2012305807B2
(en)
|
2011-09-09 |
2015-08-20 |
Department of Medical Sciences (DMSc) |
Dengue-virus serotype neutralizing antibodies
|
CA2789539A1
(en)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
CA2849073A1
(en)
|
2011-09-19 |
2013-03-28 |
Gencia Corporation |
Modified creatine compounds
|
ES2796556T3
(es)
|
2011-09-20 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Modulación antisentido de la expresión de GCGR
|
HRP20230078T1
(hr)
|
2011-09-23 |
2023-05-12 |
Mereo Biopharma 5, Inc. |
Sredstva za vezivanje vegf/dll4 i njihova uporaba
|
CA2846432A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
SG11201400879SA
(en)
|
2011-09-23 |
2014-04-28 |
Technophage Investigação E Desenvolvimento Em Biotecnologia Sa |
Anti-tumor necrosis factor-alpha agents and uses thereof
|
JP6250543B2
(ja)
|
2011-09-27 |
2017-12-20 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
ジ脂肪族置換peg化脂質
|
WO2013049749A2
(en)
|
2011-09-29 |
2013-04-04 |
Plx Pharma Inc. |
pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
CN103998058B
(zh)
|
2011-10-06 |
2021-11-05 |
免疫疫苗技术有限公司 |
包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
|
CA2850032C
(en)
|
2011-10-14 |
2022-06-07 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use
|
US8883989B2
(en)
|
2011-10-18 |
2014-11-11 |
Regents Of The University Of Minnesota |
Fractalkine binding polynucleotides and methods of use
|
AU2012328680A1
(en)
|
2011-10-25 |
2014-05-01 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of GCCR expression
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
AR088509A1
(es)
|
2011-10-28 |
2014-06-11 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma
|
EP2773662A4
(en)
|
2011-10-31 |
2015-07-01 |
Hoffmann La Roche |
ANTIBODY FORMULATIONS
|
JP6205095B2
(ja)
*
|
2011-11-03 |
2017-09-27 |
タイワン リポサム カンパニー、エルティーディー. |
疎水性カンプトテシン誘導体の医薬組成物
|
US10980798B2
(en)
|
2011-11-03 |
2021-04-20 |
Taiwan Liposome Company, Ltd. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
CA2954166A1
(en)
|
2011-11-11 |
2013-05-16 |
Rinat Neuroscience Corp. |
Antibodies specific for trop-2 and their uses
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
US9023995B2
(en)
|
2011-11-16 |
2015-05-05 |
Boehringer Ingelheim International Gmbh |
Anti IL-36R antibodies
|
EP2790730B1
(en)
|
2011-12-15 |
2019-01-23 |
The University of Chicago |
Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
|
RU2014123030A
(ru)
|
2011-12-22 |
2016-02-20 |
Ринат Ньюросайенс Корп. |
Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
EP3539982A3
(en)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
WO2013105013A1
(en)
|
2012-01-09 |
2013-07-18 |
Covx Technologies Ireland Limited |
Mutant antibodies and conjugation thereof
|
EP2804620A4
(en)
|
2012-01-18 |
2016-04-13 |
Neumedicines Inc |
IL-12 FOR RADIATION PROTECTION AND RADIATION-RELATED TOXICITY WEAKENING
|
AU2013209512B2
(en)
|
2012-01-20 |
2017-08-03 |
I2 Pharmaceuticals, Inc. |
Surrobody cojugates
|
WO2013114377A1
(en)
|
2012-02-02 |
2013-08-08 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd |
Stable liposomes for drug delivery
|
BR112014019331A2
(pt)
|
2012-02-06 |
2022-07-12 |
Inhibrx Inc |
anticorpos para cd47 e métodos de uso desses
|
MX2014009827A
(es)
*
|
2012-02-17 |
2014-09-22 |
Celsion Corp |
Formulaciones de nanoparticulas termosensibles y metodos para elaborarlas.
|
US9138492B2
(en)
*
|
2012-02-23 |
2015-09-22 |
Canon Kabushiki Kaisha |
Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle
|
US20150037334A1
(en)
|
2012-03-01 |
2015-02-05 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
AR090253A1
(es)
|
2012-03-05 |
2014-10-29 |
Gilead Calistoga Llc |
Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
|
TR201815503T4
(tr)
|
2012-03-15 |
2018-11-21 |
Curna Inc |
Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
|
WO2013149111A2
(en)
|
2012-03-29 |
2013-10-03 |
Novimmune S.A. |
Anti-tlr4 antibodies and uses thereof
|
KR20140144726A
(ko)
|
2012-03-30 |
2014-12-19 |
리젠 파마슈티컬스 소시에떼 아노님 |
C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
CA2871462A1
(en)
|
2012-04-24 |
2013-10-31 |
University Of Miami |
Perforin 2 defense against invasive and multidrug resistant pathogens
|
EP4039275A1
(en)
|
2012-05-03 |
2022-08-10 |
Boehringer Ingelheim International GmbH |
Anti-il-23p19 antibodies
|
JP6392209B2
(ja)
*
|
2012-05-04 |
2018-09-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
|
WO2013166500A1
(en)
|
2012-05-04 |
2013-11-07 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
BR112014031421A2
(pt)
|
2012-06-15 |
2017-06-27 |
Brigham & Womens Hospital Inc |
composições para tratamento de câncer e métodos para produção das mesmas
|
US9856314B2
(en)
|
2012-06-22 |
2018-01-02 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and methods of using the same
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
US20150209281A1
(en)
*
|
2012-07-18 |
2015-07-30 |
Onyx Therapeutics, Inc. |
Liposomal compositions of epoxyketone-based proteasome inhibitors
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
CN103565745A
(zh)
*
|
2012-08-10 |
2014-02-12 |
德克萨斯州大学系统董事会 |
用于治疗中风的神经保护性脂质体组合物和方法
|
SG11201408340SA
(en)
|
2012-08-14 |
2015-01-29 |
Univ Nanyang Tech |
Angiopoietin-like 4 antibody and a method of its use in cancer treatment
|
US11291644B2
(en)
|
2012-09-04 |
2022-04-05 |
Eleison Pharmaceuticals, Llc |
Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
|
EP2943194A1
(en)
|
2012-09-17 |
2015-11-18 |
Chemedest Ltd. |
Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳-法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
CA2884368C
(en)
|
2012-10-05 |
2022-01-18 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
EP2911691B1
(en)
|
2012-10-23 |
2018-10-10 |
OncoMed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
US9599620B2
(en)
|
2012-10-31 |
2017-03-21 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a DLL4 antagonist
|
JP6392770B2
(ja)
|
2012-12-03 |
2018-09-19 |
ノビミューン エスアー |
抗cd47抗体およびその使用方法
|
AU2013360302C1
(en)
|
2012-12-12 |
2019-01-24 |
Temple University - Of The Commonwealth System Of Higher Education |
Compositions and methods for treatment of cancer
|
CA2894879A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
EP2934303B1
(en)
|
2012-12-19 |
2019-09-04 |
The Research Foundation for the State University of New York |
Compositions and method for light triggered release of materials from nanovesicles
|
GB201223053D0
(en)
|
2012-12-20 |
2013-02-06 |
Medical Res Council |
Receptor
|
EP3907237A1
(en)
|
2012-12-20 |
2021-11-10 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
CA2896091C
(en)
|
2012-12-21 |
2018-06-19 |
Amplimmune, Inc. |
Anti-h7cr antibodies
|
DK2941269T3
(da)
|
2013-01-07 |
2021-01-11 |
Mucosal Vaccine Tech Llc |
Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
US10568975B2
(en)
|
2013-02-05 |
2020-02-25 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
EP2953643B1
(en)
|
2013-02-06 |
2023-02-22 |
Inhibrx, Inc. |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
EP2956169B1
(en)
|
2013-02-12 |
2018-04-11 |
THE UNITED STATES OF AMERICA, represented by the S |
Monoclonal antibodies that neutralize norovirus
|
EP2970408B1
(en)
|
2013-03-12 |
2018-01-10 |
Amgen Inc. |
Potent and selective inhibitors of nav1.7
|
WO2014152795A2
(en)
|
2013-03-14 |
2014-09-25 |
Schentag Jerome J |
Cholestosome vesicles for incorporation of molecules into chylomicrons
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
US10052364B2
(en)
|
2013-03-15 |
2018-08-21 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
KR20150132473A
(ko)
|
2013-03-15 |
2015-11-25 |
다이액스 코포레이션 |
항-혈장 칼리크레인 항체
|
WO2014145037A1
(en)
*
|
2013-03-15 |
2014-09-18 |
M. Alphabet 3, L.L.C. |
Methods and compositions for enhancing oxygen levels in tissues
|
TW201525001A
(zh)
|
2013-03-15 |
2015-07-01 |
Amgen Res Munich Gmbh |
包含n-端abp之單鏈結合分子
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
BR112015023664A2
(pt)
|
2013-03-15 |
2017-10-24 |
Gencia Corp |
composições e métodos para tratamento de condições que afetam a epiderme
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
WO2014145654A1
(en)
|
2013-03-15 |
2014-09-18 |
The Trustees Of The University Of Pennsylvania |
Method for the site-specific covalent cross-linking of antibodies to surfaces
|
JP6427552B2
(ja)
|
2013-03-15 |
2018-11-21 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
フラビウイルス中和抗体およびその使用方法
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
SG11201507974RA
(en)
|
2013-03-27 |
2015-10-29 |
Genentech Inc |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
EP3708184A1
(en)
|
2013-03-27 |
2020-09-16 |
The General Hospital Corporation |
Methods and agents for treating alzheimer s disease
|
WO2014169272A1
(en)
|
2013-04-12 |
2014-10-16 |
Icahn School Of Medicine At Mount Sinai |
Method for treating post-traumatic stress disorder
|
EP2992000B1
(en)
|
2013-05-03 |
2020-07-08 |
The Regents of The University of California |
Cyclic di-nucleotide induction of type i interferon
|
SG10201913751RA
(en)
|
2013-05-06 |
2020-03-30 |
Scholar Rock Inc |
Compositions and methods for growth factor modulation
|
EP2994167B1
(en)
|
2013-05-06 |
2020-05-06 |
Alnylam Pharmaceuticals, Inc. |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
CN105189560A
(zh)
|
2013-05-07 |
2015-12-23 |
瑞纳神经科学公司 |
抗胰高血糖素受体抗体和其使用方法
|
WO2014183052A1
(en)
|
2013-05-09 |
2014-11-13 |
The United States Of America, As Represented By The Secretary, Depart Of Health And Human Services |
Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
|
BR112015029395A2
(pt)
|
2013-05-24 |
2017-09-19 |
Medimmune Llc |
Anticorpos anti-b7-h5 e seus usos
|
EP3381939A1
(en)
|
2013-05-31 |
2018-10-03 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
MX369758B
(es)
|
2013-05-31 |
2019-11-20 |
Genentech Inc |
Anticuerpos anti-acido teicoico de pared y conjugados.
|
SG11201509982UA
(nl)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
JP6869720B2
(ja)
|
2013-06-13 |
2021-05-12 |
アンチセンス セラピューティクス リミテッド |
併用療法
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
WO2015013671A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
WO2015017807A1
(en)
*
|
2013-08-01 |
2015-02-05 |
University Of Georgia Research Foundation, Inc. |
Liposomal formulations for the treatment of bacterial infections
|
PE20160671A1
(es)
|
2013-08-02 |
2016-07-09 |
Pfizer |
Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
|
MX2016001854A
(es)
|
2013-08-12 |
2016-09-06 |
Genentech Inc |
Composiciones y metodo para tratar condiciones asociadas con el complemento.
|
JP6617239B2
(ja)
|
2013-08-14 |
2019-12-11 |
サイドゥ サチデーブ |
Frizzledタンパク質に対する抗体及びその使用方法
|
JP2016529284A
(ja)
*
|
2013-08-27 |
2016-09-23 |
ノースイースタン ユニバーシティ |
ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法
|
EP3690048A1
(en)
|
2013-09-04 |
2020-08-05 |
Cold Spring Harbor Laboratory |
Reducing nonsense-mediated mrna decay
|
CA2922838A1
(en)
|
2013-09-05 |
2015-03-12 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向cd33及cd3之雙特異性化合物的組合
|
PT3046537T
(pt)
*
|
2013-09-16 |
2021-10-07 |
Glycomine Inc |
Preparação farmacêutica de hidratos de carbono para utilização terapêutica
|
DE102013015334A1
(de)
*
|
2013-09-17 |
2015-03-19 |
Fresenius Medical Care Deutschland Gmbh |
Magnesium-Liposomen-Komplexe
|
WO2015042466A2
(en)
|
2013-09-19 |
2015-03-26 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for inhibiting jc virus (jcv)
|
WO2015048329A2
(en)
|
2013-09-25 |
2015-04-02 |
Cytomx Therapeutics, Inc. |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
US10259875B2
(en)
|
2013-10-01 |
2019-04-16 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer in patients with elevated levels of BIM
|
TWI669393B
(zh)
|
2013-10-02 |
2019-08-21 |
艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
EP3052628B1
(en)
|
2013-10-04 |
2020-02-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
JPWO2015068781A1
(ja)
|
2013-11-06 |
2017-03-09 |
国立大学法人大阪大学 |
インフルエンザウイルスa型のグループ1に対して広域な中和活性を有する抗体
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
JP2017505756A
(ja)
|
2013-12-13 |
2017-02-23 |
ザ ジェネラル ホスピタル コーポレイション |
可溶性高分子量(hmw)タウ種およびその用途
|
AU2014364414A1
(en)
|
2013-12-20 |
2016-06-30 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
|
EA201690990A1
(ru)
|
2013-12-20 |
2016-11-30 |
Джилид Калистога Ллс |
Способы получения ингибиторов фосфатидилинозитол-3-киназы
|
CN106102725A
(zh)
|
2014-01-14 |
2016-11-09 |
约翰斯·霍普金斯大学 |
包封选择性atp抑制剂的环糊精组合物及其应用
|
AU2015315834B2
(en)
|
2014-01-31 |
2019-12-12 |
Boehringer Ingelheim International Gmbh |
Novel anti-BAFF antibodies
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
IL302642A
(en)
|
2014-01-31 |
2023-07-01 |
Cytomx Therapeutics Inc |
Polypeptide substrates that activate matriptase and U-plasminogen and other cleavable groups, preparations containing them and their uses
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
JP6870988B2
(ja)
|
2014-02-24 |
2021-05-19 |
セルジーン コーポレイション |
神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
EP4043489A1
(en)
|
2014-03-19 |
2022-08-17 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
WO2015143409A1
(en)
|
2014-03-21 |
2015-09-24 |
Labrys Biologics, Inc. |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
CN113604543A
(zh)
|
2014-03-27 |
2021-11-05 |
豪夫迈·罗氏有限公司 |
用于诊断和治疗炎症性肠病的方法
|
AU2015241198A1
(en)
|
2014-04-03 |
2016-11-17 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
KR20160145813A
(ko)
|
2014-04-25 |
2016-12-20 |
다나-파버 캔서 인스티튜트 인크. |
중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
|
EP3139955B1
(en)
|
2014-04-30 |
2024-03-20 |
President and Fellows of Harvard College |
Fusion proteins for treating cancer and related methods
|
EP3137114B8
(en)
|
2014-04-30 |
2021-08-04 |
Pfizer Inc. |
Anti-ptk7 antibody-drug conjugates
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
EP3143043B1
(en)
|
2014-05-16 |
2022-12-14 |
Pfizer Inc. |
Bispecific antibodies with engineered ch1-cl interfaces
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
EA028614B1
(ru)
|
2014-05-22 |
2017-12-29 |
Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" |
Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
|
TWI689520B
(zh)
|
2014-05-30 |
2020-04-01 |
漢霖生技股份有限公司 |
抗表皮生長因子受體(egfr)抗體
|
WO2015191781A2
(en)
|
2014-06-10 |
2015-12-17 |
Amgen Inc. |
Apelin polypeptides
|
EA201692202A1
(ru)
|
2014-06-11 |
2017-06-30 |
Джилид Сайэнс, Инк. |
Способы лечения сердечно-сосудистых заболеваний
|
CA2952012A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
US10562946B2
(en)
|
2014-06-20 |
2020-02-18 |
Genentech, Inc. |
Chagasin-based scaffold compositions, methods, and uses
|
EP3160503B1
(en)
|
2014-06-26 |
2021-02-17 |
The Trustees of Columbia University in the City of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
BR112017001579A2
(pt)
|
2014-07-25 |
2017-11-21 |
Cytomx Therapeutics Inc |
anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
AR101936A1
(es)
|
2014-07-31 |
2017-01-25 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
|
WO2016020798A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016034968A1
(en)
|
2014-09-02 |
2016-03-10 |
Pfizer Inc. |
Therapeutic antibody
|
EP3197492A1
(en)
|
2014-09-23 |
2017-08-02 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
RU2017115315A
(ru)
|
2014-10-03 |
2018-11-08 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
|
GB201417589D0
(en)
|
2014-10-06 |
2014-11-19 |
Cantab Biopharmaceuticals Patents Ltd |
Pharmaceutical Formulations
|
EP3699196A1
(en)
|
2014-10-06 |
2020-08-26 |
Dana Farber Cancer Institute, Inc. |
Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
|
CN107530419B
(zh)
|
2014-10-31 |
2021-05-18 |
昂考梅德药品有限公司 |
治疗疾病的组合疗法
|
FI3218005T3
(fi)
|
2014-11-12 |
2023-03-31 |
Seagen Inc |
Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
|
WO2016077566A1
(en)
|
2014-11-12 |
2016-05-19 |
Research Institute At Nationwide Children's Hospital |
Modulation of alternative mdm2 splicing
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2016081728A1
(en)
|
2014-11-19 |
2016-05-26 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
KR20170086536A
(ko)
|
2014-12-03 |
2017-07-26 |
제넨테크, 인크. |
항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
|
RU2017118792A
(ru)
|
2014-12-03 |
2019-01-09 |
Дженентек, Инк. |
Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
|
WO2016090170A1
(en)
|
2014-12-05 |
2016-06-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A potent anti-influenza a neuraminidase subtype n1 antibody
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
NZ733055A
(en)
|
2014-12-11 |
2023-03-31 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
EA201791337A1
(ru)
|
2014-12-15 |
2017-11-30 |
Дзе Джонс Хопкинс Юниверсити |
Составы сунитиниба и способы их применения в лечении глазных нарушений
|
CA2970795A1
(en)
|
2014-12-18 |
2016-06-23 |
Alnylam Pharmaceuticals, Inc. |
Reversir compounds
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
CA2974369A1
(en)
|
2015-01-20 |
2016-07-28 |
The Children's Medical Center Corporation |
Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
|
EP3250184A1
(en)
|
2015-01-27 |
2017-12-06 |
The Johns Hopkins University |
Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック, インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
JP2018506526A
(ja)
|
2015-01-29 |
2018-03-08 |
ボード オブ トラスティーズ オブ ミシガン ステイト ユニバーシティBoard Of Trustees Of Michigan State University |
クリプティックポリペプチドおよびその使用
|
WO2016134066A1
(en)
*
|
2015-02-17 |
2016-08-25 |
Mallinckrodt Llc |
Modified docetaxel liposome formulations and uses thereof
|
LT3653221T
(lt)
|
2015-02-19 |
2022-11-10 |
Compugen Ltd. |
Anti-pvrig antikūnai ir naudojimo būdai
|
DK3259597T3
(da)
|
2015-02-19 |
2022-05-09 |
Compugen Ltd |
Pvrig-polypeptider og fremgangsmåder til behandling
|
AU2016222683A1
(en)
|
2015-02-26 |
2017-07-13 |
Genentech, Inc. |
Integrin beta7 antagonists and methods of treating crohn's disease
|
LT3265123T
(lt)
|
2015-03-03 |
2023-01-25 |
Kymab Limited |
Antikūnai, naudojimas ir būdai
|
US9895313B2
(en)
|
2015-03-03 |
2018-02-20 |
Cureport, Inc. |
Combination liposomal pharmaceutical formulations
|
CN107530291A
(zh)
*
|
2015-03-03 |
2018-01-02 |
奎尔波特股份有限公司 |
双重负载的脂质体药物制剂
|
BR112017019559B1
(pt)
|
2015-03-13 |
2020-08-04 |
Cytomx Therapeutics, Inc |
Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes
|
JP6859275B2
(ja)
|
2015-03-17 |
2021-04-14 |
リポメディックス・ファーマシューティカルズ・リミテッドLipomedix Pharmaceuticals Ltd. |
膀胱がんの治療方法
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
CN107750253B
(zh)
|
2015-04-08 |
2022-10-04 |
达纳-法伯癌症研究所公司 |
人源化流感单克隆抗体及其使用方法
|
CA3219684A1
(en)
|
2015-04-13 |
2016-10-13 |
Pfizer Inc. |
Anti-bcma antibodies, anti-cd3 antibodies and bi-specific antibodies binding to bcma and cd3
|
LT3283524T
(lt)
|
2015-04-17 |
2023-05-25 |
Amgen Research (Munich) Gmbh |
Bispecifiniai antikūnų konstruktai, skirti cdh3 ir cd3
|
EP3288977B1
(en)
|
2015-05-01 |
2021-11-17 |
Dana-Farber Cancer Institute, Inc. |
Methods of mediating cytokine expression with anti ccr4 antibodies
|
MX2017014136A
(es)
|
2015-05-04 |
2018-07-06 |
Cytomx Therapeutics Inc |
Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
|
RS62956B1
(sr)
|
2015-05-04 |
2022-03-31 |
Cytomx Therapeutics Inc |
Anti-cd71 antitela koja se mogu aktivirati, i postupci njihove upotrebe
|
BR112017023868A2
(pt)
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
|
EP3294334B1
(en)
|
2015-05-11 |
2020-07-08 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
WO2016180986A1
(en)
|
2015-05-14 |
2016-11-17 |
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) |
Mirna compositions for the treatment of mature b-cell neoplasms
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
WO2016196381A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Pd-l1 promoter methylation in cancer
|
MA50829A
(fr)
|
2015-06-01 |
2018-04-11 |
Sarepta Therapeutics Inc |
Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
|
ES2932801T3
(es)
|
2015-06-10 |
2023-01-26 |
Elysium Health Inc |
Composiciones de ribósido de nicotinamida y pterostilbeno y métodos para el tratamiento de trastornos de la piel
|
CN108024535A
(zh)
|
2015-07-02 |
2018-05-11 |
大塚制药株式会社 |
冻干药物组合物
|
SG10201913303XA
(en)
|
2015-07-13 |
2020-03-30 |
Cytomx Therapeutics Inc |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
CA2991980A1
(en)
|
2015-07-13 |
2017-01-19 |
Compugen Ltd. |
Hide1 compositions and methods
|
WO2017015109A1
(en)
|
2015-07-17 |
2017-01-26 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
CA2993026A1
(en)
|
2015-07-21 |
2017-01-26 |
Dyax Corp. |
A monoclonal antibody inhibitor of factor xiia
|
EP3328886B1
(en)
|
2015-07-29 |
2020-09-16 |
Allergan, Inc. |
Heavy chain only antibodies to ang-2
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
JP2018523673A
(ja)
|
2015-08-14 |
2018-08-23 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
Pdgfに対する重鎖のみ抗体
|
WO2017031442A1
(en)
|
2015-08-20 |
2017-02-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
|
CN108495629A
(zh)
|
2015-08-21 |
2018-09-04 |
益普生生物制药有限公司 |
使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法
|
US20170058038A1
(en)
|
2015-09-01 |
2017-03-02 |
Boehringer Ingelheim International Gmbh |
Use of anti-cd40 antibodies for treatment of lupus nephritis
|
WO2017048843A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
LT3350220T
(lt)
|
2015-09-15 |
2021-09-27 |
Scholar Rock, Inc. |
Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
US11339213B2
(en)
|
2015-09-23 |
2022-05-24 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
WO2017058881A1
(en)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
CN108431038A
(zh)
|
2015-10-06 |
2018-08-21 |
豪夫迈·罗氏有限公司 |
治疗多发性硬化的方法
|
MA45819A
(fr)
|
2015-10-09 |
2018-08-15 |
Sarepta Therapeutics Inc |
Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
|
GB201518170D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
|
GB201518171D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for topical administration with therapeutic agent
|
GB201518172D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for use in medicine
|
WO2017066726A1
(en)
|
2015-10-16 |
2017-04-20 |
Merrimack Pharmaceuticals, Inc. |
Stabilizing camptothecin pharmaceutical compositions
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
SG10202001808VA
(en)
|
2015-10-30 |
2020-04-29 |
Genentech Inc |
Anti-htra1 antibodies and methods of use thereof
|
CA3007424A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
EP3370712A4
(en)
|
2015-11-06 |
2019-10-09 |
The Johns Hopkins University |
METHODS OF TREATING HEPATIC FIBROSIS BY ADMINISTERING 3-BROMOPYRUVATE
|
US11116726B2
(en)
|
2015-11-10 |
2021-09-14 |
Childrens Research Institute, Childrens National Medical Center |
Echinomycin formulation, method of making and method of use thereof
|
CA3004886A1
(en)
|
2015-11-12 |
2017-05-18 |
Graybug Vision, Inc. |
Aggregating microparticles for medical therapy
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
TWI778491B
(zh)
|
2015-11-30 |
2022-09-21 |
美商輝瑞股份有限公司 |
位點專一性her2抗體藥物共軛體
|
TWI812873B
(zh)
|
2015-11-30 |
2023-08-21 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
EP3383908A1
(en)
|
2015-12-02 |
2018-10-10 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
WO2017096051A1
(en)
|
2015-12-02 |
2017-06-08 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
US20190307857A1
(en)
|
2015-12-09 |
2019-10-10 |
Modernatx, Inc. |
MODIFIED mRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF
|
WO2017105990A1
(en)
|
2015-12-14 |
2017-06-22 |
Massachusetts Institute Of Technology |
Ph-responsive mucoadhesive polymeric encapsulated microorganisms
|
US11433136B2
(en)
|
2015-12-18 |
2022-09-06 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
JPWO2017110772A1
(ja)
|
2015-12-21 |
2018-09-13 |
富士フイルム株式会社 |
リポソーム及びリポソーム組成物
|
CA3009378A1
(en)
|
2015-12-23 |
2017-06-29 |
Queensland University Of Technology |
Nucleic acid oligomers and uses therefor
|
US11719704B2
(en)
|
2015-12-30 |
2023-08-08 |
Momenta Pharmaceuticals, Inc. |
Methods related to biologics
|
MX2018008369A
(es)
|
2016-01-08 |
2019-05-15 |
Scholar Rock Inc |
Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
|
WO2017127750A1
(en)
|
2016-01-22 |
2017-07-27 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
包含雙特異性抗體建構物之醫藥組合物
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
BR112018015415A2
(pt)
|
2016-02-03 |
2018-12-18 |
Amgen Res Munich Gmbh |
célula t biespecífica de psma e cd3 de engate de construtos de anticorpos
|
TWI748984B
(zh)
|
2016-02-03 |
2021-12-11 |
德商安美基研究(慕尼黑)公司 |
Bcma及cd3雙特異性t細胞嚙合抗體構築體
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
JP7157981B2
(ja)
|
2016-03-07 |
2022-10-21 |
チャールストンファーマ, エルエルシー |
抗ヌクレオリン抗体
|
US11633502B2
(en)
*
|
2016-03-07 |
2023-04-25 |
Memorial Sloan Kettering Cancer Center |
Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
|
KR20230088508A
(ko)
|
2016-03-11 |
2023-06-19 |
스칼러 락, 인크. |
TGFβ1-결합 이뮤노글로불린 및 그의 용도
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
MX2018012695A
(es)
|
2016-04-18 |
2019-06-20 |
Sarepta Therapeutics Inc |
Oligomeros antisentido y metodos de uso de los mismos para tratar enfermedades relacionadas con el gen alpha-glucosidasa acido.
|
CN109069473B
(zh)
|
2016-04-21 |
2022-09-16 |
港大科桥有限公司 |
用于亮肤和减少色素沉着过度的组合物和方法
|
CA3026880A1
(en)
|
2016-06-08 |
2017-12-14 |
Paul Foster |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
ITUA20164630A1
(it)
|
2016-06-23 |
2017-12-23 |
Paolo Blasi |
Adiuvanti farmacologici per la termoablazione tumorale
|
ES2887573T3
(es)
|
2016-06-27 |
2021-12-23 |
Alexion Pharma Inc |
Métodos para el tratamiento de la hipofosfatasia en niños y adolescentes
|
WO2018005657A1
(en)
|
2016-06-28 |
2018-01-04 |
Verily Life Sciences Llc |
Serial filtration to generate small cholesterol-containing liposomes
|
BR112019001262A2
(pt)
|
2016-07-22 |
2019-05-07 |
Dana-Farber Cancer Institute, Inc. |
anticorpos para o receptor do fator de necrose de tumor induzido por glicocorticoide (gitr) e métodos de uso dos mesmos
|
KR20240035633A
(ko)
|
2016-08-03 |
2024-03-15 |
넥스트큐어 인코포레이티드 |
Lair 신호 변환을 조정하기 위한 조성물 및 방법
|
WO2018026890A1
(en)
|
2016-08-03 |
2018-02-08 |
Cymabay Therapeutics |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
TWI754659B
(zh)
|
2016-08-08 |
2022-02-11 |
台灣微脂體股份有限公司 |
用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
|
EP3507305A1
(en)
|
2016-09-02 |
2019-07-10 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
BR112019004214A2
(pt)
|
2016-09-06 |
2019-05-28 |
Dana Farber Cancer Inst Inc |
métodos para tratar ou prevenir infecção pelo vírus zika
|
WO2018049275A1
(en)
|
2016-09-09 |
2018-03-15 |
Genentech, Inc. |
Selective peptide inhibitors of frizzled
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
CA3036829A1
(en)
|
2016-09-14 |
2018-03-22 |
The Trustees Of The University Of Pennsylvania |
Proximity-based sortase-mediated protein purification and ligation
|
AU2017327828B2
(en)
|
2016-09-16 |
2023-11-16 |
Shanghai Henlius Biotech, Inc. |
Anti-PD-1 antibodies
|
CA3037661A1
(en)
|
2016-09-23 |
2018-03-29 |
Teva Pharmaceuticals International Gmbh |
Treating cluster headache
|
BR112019005823A2
(pt)
|
2016-09-23 |
2019-06-25 |
Teva Pharmaceuticals Int Gmbh |
tratamento para enxaqueca refratária
|
EP3532070A1
(en)
|
2016-10-26 |
2019-09-04 |
Modernatx, Inc. |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
MA46709A
(fr)
|
2016-11-02 |
2019-09-11 |
Ipsen Biopharm Ltd |
Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
CA3040812A1
(en)
|
2016-11-04 |
2018-05-11 |
Novimmune Sa |
Anti-cd19 antibodies and methods of use thereof
|
JP2020500020A
(ja)
|
2016-11-14 |
2020-01-09 |
ノバルティス アーゲー |
融合誘導性タンパク質minionに関連する組成物、方法、および治療上の使用
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
GEP20217265B
(en)
|
2016-12-16 |
2021-06-25 |
Pfizer |
Glp-1 receptor agonists and uses thereof
|
US10772926B2
(en)
|
2016-12-16 |
2020-09-15 |
Nutragen Health Innovations, Inc. |
Natural drugs for the treatment of inflammation and melanoma
|
FI3565592T3
(fi)
|
2017-01-06 |
2023-05-10 |
Scholar Rock Inc |
Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio
|
CA3049005A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
Isoform-specific, context-permissive tgf.beta.1 inhibitors and use thereof
|
PT3565592T
(pt)
|
2017-01-06 |
2023-05-31 |
Scholar Rock Inc |
Tratamento de doenças metabólicas através da inibição da ativação da miostatina
|
CN117224710A
(zh)
|
2017-02-01 |
2023-12-15 |
莫得纳特斯公司 |
编码活化致癌基因突变肽的免疫调节治疗性mrna组合物
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
PE20191487A1
(es)
|
2017-03-03 |
2019-10-18 |
Rinat Neuroscience Corp |
Anticuerpos anti-gitr y metodos de uso de los mismos
|
SG11201907889YA
(en)
|
2017-03-03 |
2019-09-27 |
Seattle Genetics Inc |
Glycan-interacting compounds and methods of use
|
WO2018165619A1
(en)
|
2017-03-09 |
2018-09-13 |
Cytomx Therapeutics, Inc. |
Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
|
EP3601350A1
(en)
|
2017-03-27 |
2020-02-05 |
Boehringer Ingelheim International GmbH |
Anti il-36r antibodies combination therapy
|
US11359200B2
(en)
|
2017-04-09 |
2022-06-14 |
The Cleveland Clinic Foundation |
Cancer treatment by MALAT1 inhibition
|
US20230192839A1
(en)
|
2017-04-12 |
2023-06-22 |
Pfizer Inc. |
Antibodies having conditional affinity and methods of use thereof
|
WO2018191548A2
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
EP3612625A4
(en)
|
2017-04-21 |
2021-08-18 |
Mellitus, LLC |
PROCEDURE AND ANTIBODIES FOR DIABETES ASSOCIATED APPLICATIONS
|
US11236151B2
(en)
|
2017-04-25 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
|
BR112019022751A2
(pt)
|
2017-05-05 |
2020-05-19 |
Amgen Inc |
composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
|
US11318190B2
(en)
|
2017-05-05 |
2022-05-03 |
United States Government As Represented By The Department Of Veterans Affairs |
Methods and compositions for treating liver disease
|
US11160870B2
(en)
|
2017-05-10 |
2021-11-02 |
Graybug Vision, Inc. |
Extended release microparticles and suspensions thereof for medical therapy
|
SG11201909751TA
(en)
|
2017-05-12 |
2019-11-28 |
Augusta University Research Institute Inc |
Human alpha fetoprotein-specific t cell receptors and uses thereof
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
US11260117B2
(en)
|
2017-05-26 |
2022-03-01 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
CA3065300A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
EP3630835A1
(en)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
BR112019025188A2
(pt)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
EP3635007A1
(en)
|
2017-06-06 |
2020-04-15 |
STCube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
CA3061752A1
(en)
|
2017-07-06 |
2019-01-10 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of alpha-enac and methods of use
|
EP3651799A1
(en)
|
2017-07-13 |
2020-05-20 |
Massachusetts Institute of Technology |
Targeting the hdac2-sp3 complex to enhance synaptic function
|
KR20200027971A
(ko)
|
2017-07-14 |
2020-03-13 |
싸이톰스 테라퓨틱스, 인크. |
항-cd166 항체 및 이의 용도
|
EP3655430A1
(en)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
US20210025877A1
(en)
|
2017-07-20 |
2021-01-28 |
CytomX Therapeutices, Inc. |
Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
WO2019018765A1
(en)
|
2017-07-21 |
2019-01-24 |
Modernatx, Inc. |
MODIFIED mRNA ENCODING PROPIONYL-COA-CARBOXYLASE AND USES THEREOF
|
US20200179494A1
(en)
|
2017-07-24 |
2020-06-11 |
Modernatx, Inc. |
Modified mRNA Encoding a Glucose 6 Phosphatase and Uses Thereof
|
PT3658184T
(pt)
|
2017-07-27 |
2023-11-29 |
Alexion Pharma Inc |
Formulações de anticorpo anti-c5 de elevada concentração
|
EP3658583A1
(en)
|
2017-07-28 |
2020-06-03 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
|
CA3071755A1
(en)
|
2017-08-03 |
2019-02-07 |
Otsuka Pharmaceutical Co., Ltd. |
Drug compound and purification methods thereof
|
US11135187B2
(en)
|
2017-08-22 |
2021-10-05 |
National Institutes Of Health (Nih) |
Compositions and methods for treating diabetic retinopathy
|
WO2019046652A1
(en)
|
2017-08-30 |
2019-03-07 |
Cytomx Therapeutics, Inc. |
ANTI-CD166 ACTIVABLE ANTIBODIES, AND METHODS OF USE
|
WO2019051164A1
(en)
|
2017-09-07 |
2019-03-14 |
Augusta University Research Institute, Inc. |
ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
|
US11999953B2
(en)
|
2017-09-13 |
2024-06-04 |
The Children's Medical Center Corporation |
Compositions and methods for treating transposon associated diseases
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
JP2020536967A
(ja)
|
2017-10-12 |
2020-12-17 |
イミュノウェイク インコーポレイテッド |
Vegfr−抗体軽鎖融合タンパク質
|
WO2019075405A1
(en)
|
2017-10-14 |
2019-04-18 |
Cytomx Therapeutics, Inc. |
ANTIBODIES, ACTIVISTIC ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFICALLY ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF
|
AU2018353533A1
(en)
|
2017-10-17 |
2020-05-28 |
Rhizen Pharmaceuticals Sa |
CRAC channel modulators for treating esophageal cancer
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
WO2019082124A1
(en)
|
2017-10-26 |
2019-05-02 |
Rhizen Pharmaceuticals Sa |
COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA
|
CN111556876A
(zh)
|
2017-10-27 |
2020-08-18 |
辉瑞公司 |
对cd123具有特异性的抗体和抗体-药物缀合物及其用途
|
WO2019087047A1
(en)
|
2017-10-30 |
2019-05-09 |
Rhizen Pharmaceuticals Sa |
Calcium release-activated calcium channel modulators for treating hematological and solid cancers
|
WO2019086626A1
(en)
|
2017-11-03 |
2019-05-09 |
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) |
MIRNAs AND COMBINATIONS THEREOF FOR USE IN THE TREATMENT OF HUMAN B CELL NEOPLASIAS
|
EA202091082A1
(ru)
|
2017-12-06 |
2020-10-23 |
Ризен Фармасьютикалз Са |
Композиция и способ лечения периферической т-клеточной лимфомы и кожной т-клеточной лимфомы
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
CN111315780A
(zh)
|
2017-12-11 |
2020-06-19 |
安进公司 |
双特异性抗体产品的连续制造工艺
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
WO2019165101A1
(en)
|
2018-02-22 |
2019-08-29 |
Verily Life Sciences Llc |
Combining orthogonal chemistries for preparation of multiplexed nanoparticles
|
WO2019166946A1
(en)
|
2018-02-28 |
2019-09-06 |
Pfizer Inc. |
Il-15 variants and uses thereof
|
WO2019173771A1
(en)
|
2018-03-09 |
2019-09-12 |
Cytomx Therapeutics, Inc. |
Activatable cd147 antibodies and methods of making and use thereof
|
CA3093330A1
(en)
|
2018-03-14 |
2019-09-19 |
Novimmune Sa |
Anti-cd3 epsilon antibodies and methods of use thereof
|
BR112020014591A2
(pt)
|
2018-03-14 |
2020-12-01 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
anticorpos anticlaudina 18.2
|
US20210000936A1
(en)
|
2018-03-21 |
2021-01-07 |
Colorado State University Research Foundation |
Cancer vaccine compositions and methods of use thereof
|
US10722528B2
(en)
|
2018-03-28 |
2020-07-28 |
Augusta University Research Institute, Inc. |
Compositions and methods for inhibiting metastasis
|
WO2019195738A1
(en)
|
2018-04-06 |
2019-10-10 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
CN112334485A
(zh)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
|
WO2019197607A1
(en)
|
2018-04-13 |
2019-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fc-engineered anti-human ige antibodies and methods of use
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
US11434292B2
(en)
|
2018-05-23 |
2022-09-06 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
AU2019274655B2
(en)
|
2018-05-23 |
2023-03-09 |
Pfizer Inc. |
Antibodies specific for GUCY2c and uses thereof
|
WO2019234680A1
(en)
|
2018-06-08 |
2019-12-12 |
Pfizer Inc. |
Methods of treating iron metabolic disease with a neutralizing antibody binding erhythroferrone
|
TWI707683B
(zh)
|
2018-06-13 |
2020-10-21 |
美商輝瑞股份有限公司 |
Glp-1受體促效劑及其用途
|
DK3806855T5
(da)
|
2018-06-15 |
2023-05-22 |
Pfizer |
GLP-1-receptoragonister og anvendelser deraf
|
EP3810189A1
(en)
|
2018-06-19 |
2021-04-28 |
Armo Biosciences, Inc. |
Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
|
AU2019293286A1
(en)
|
2018-06-28 |
2021-01-07 |
Crispr Therapeutics Ag |
Compositions and methods for genomic editing by insertion of donor polynucleotides
|
EA202190094A1
(ru)
|
2018-06-29 |
2021-04-21 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Антитела против cd40 для применения в лечении аутоиммунного заболевания
|
CA3105161C
(en)
|
2018-07-06 |
2022-11-15 |
Pfizer Inc. |
Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
|
WO2020014460A1
(en)
|
2018-07-11 |
2020-01-16 |
Scholar Rock, Inc. |
HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
|
TW202019957A
(zh)
|
2018-07-11 |
2020-06-01 |
美商供石公司 |
TGFβ1抑制劑及其用途
|
EP3677278B1
(en)
|
2018-07-11 |
2021-11-10 |
Scholar Rock, Inc. |
Isoform selective tgfbeta1 inhibitors and use thereof
|
MA53160A
(fr)
|
2018-07-20 |
2021-05-26 |
Pf Medicament |
Récepteur pour vista
|
EP3837367A1
(en)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
EP3849515A1
(en)
*
|
2018-09-11 |
2021-07-21 |
Memorial Sloan Kettering Cancer Center |
Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
|
CN113365697A
(zh)
|
2018-09-25 |
2021-09-07 |
百进生物科技公司 |
抗tlr9药剂和组合物及其制备方法和使用方法
|
JP2022513328A
(ja)
|
2018-09-27 |
2022-02-07 |
フォスフォガム, インコーポレイテッド |
同種異系のガンマ/デルタt細胞の増殖および使用のための方法および組成物
|
JP2022503961A
(ja)
|
2018-09-28 |
2022-01-12 |
リビジェン バイオファーマ カンパニー リミテッド |
操作されたFcドメインを有する抗CD40結合分子およびその治療用途
|
KR20210074341A
(ko)
|
2018-10-10 |
2021-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
|
CN112789058A
(zh)
|
2018-10-11 |
2021-05-11 |
安进公司 |
双特异性抗体构建体的下游加工
|
US11427591B2
(en)
|
2018-10-17 |
2022-08-30 |
Insilico Medicine Ip Limited |
Kinase inhibitors
|
SG11202104010PA
(en)
|
2018-10-23 |
2021-05-28 |
Scholar Rock Inc |
Rgmc-selective inhibitors and use thereof
|
CN113260383A
(zh)
|
2018-11-02 |
2021-08-13 |
西托姆克斯治疗公司 |
可活化的抗cd166抗体及其使用方法
|
KR20210106447A
(ko)
|
2018-11-22 |
2021-08-30 |
치루 레고르 테라퓨틱스 인코포레이티드 |
Glp-1r 효능제 및 그의 용도
|
EP3887516A1
(en)
|
2018-11-29 |
2021-10-06 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating rna
|
KR20210102318A
(ko)
|
2018-12-06 |
2021-08-19 |
싸이톰스 테라퓨틱스, 인크. |
매트릭스 메탈로프로테이스-절단성 기질 및 세린 또는 시스테인 프로테이스-절단성 기질 그리고 이들의 사용 방법
|
BR112021012172A2
(pt)
|
2018-12-12 |
2021-08-31 |
Kite Pharma, Inc. |
Receptores de antígenos quiméricos e de célula t e métodos de uso
|
WO2020154374A1
(en)
|
2019-01-22 |
2020-07-30 |
Massachusetts Institute Of Technology |
In vitro human blood brain barrier
|
JP2020117502A
(ja)
|
2019-01-28 |
2020-08-06 |
ファイザー・インク |
変形性関節症の徴候および症状を処置する方法
|
CA3128042A1
(en)
|
2019-01-30 |
2020-08-06 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgf.beta. and uses thereof
|
US20220144846A1
(en)
|
2019-02-15 |
2022-05-12 |
Pfizer Inc. |
Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
|
EP3927430A1
(en)
|
2019-02-18 |
2021-12-29 |
Pfizer Inc. |
Method of treatment of chronic low back pain
|
US20220275059A1
(en)
|
2019-02-20 |
2022-09-01 |
Harbour Antibodies Bv |
Antibodies
|
US11795160B2
(en)
|
2019-02-22 |
2023-10-24 |
Insilico Medicine Ip Limited |
Kinase inhibitors
|
CN113677372A
(zh)
|
2019-02-26 |
2021-11-19 |
西托姆克斯治疗公司 |
可活化免疫检查点抑制剂和经缀合可活化抗体的组合疗法
|
US20200283796A1
(en)
|
2019-03-05 |
2020-09-10 |
Massachusetts Institute Of Technology |
Dna launched rna replicon system (drep) and uses thereof
|
WO2020185293A1
(en)
|
2019-03-08 |
2020-09-17 |
Massachusetts Institute Of Technology |
Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
|
WO2020197400A1
(en)
|
2019-03-27 |
2020-10-01 |
Umc Utrecht Holding B.V. |
Engineered iga antibodies and methods of use
|
AR118536A1
(es)
|
2019-04-01 |
2021-10-20 |
Genentech Inc |
Composiciones y métodos para estabilizar formulaciones que contienen proteína
|
EP3947367A1
(en)
|
2019-04-02 |
2022-02-09 |
Array Biopharma, Inc. |
Protein tyrosine phosphatase inhibitors
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
JP7498199B2
(ja)
|
2019-06-28 |
2024-06-11 |
ファイザー・インク |
種々の疾患を処置するために有用なbckdk阻害剤としての5-(チオフェン-2-イル)-1h-テトラゾール誘導体
|
LT6699B
(lt)
|
2019-07-15 |
2020-02-10 |
UAB "Valentis" |
Proliposomų gamybos būdas, naudojant ne daugiau kaip 5 % etanolio, ir jų panaudojimas lipofilinių medžiagų kapsuliavimui
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
US10758329B1
(en)
|
2019-08-20 |
2020-09-01 |
Raymond L. Wright, III |
Hydrating mouth guard
|
MX2022002689A
(es)
|
2019-09-03 |
2022-04-07 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2).
|
JP2022548310A
(ja)
|
2019-09-23 |
2022-11-17 |
シートムエックス セラピューティクス,インコーポレイテッド |
抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法
|
CN114729045A
(zh)
|
2019-09-26 |
2022-07-08 |
斯特库比公司 |
对糖基化的ctla-4特异性的抗体及其使用方法
|
WO2021062092A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Trans-activated functional rna by strand displacement and uses thereof
|
WO2021062096A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Microrna-based logic gates and uses thereof
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021071830A1
(en)
|
2019-10-07 |
2021-04-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
EP4041773A1
(en)
|
2019-10-11 |
2022-08-17 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
JP2023501912A
(ja)
|
2019-10-21 |
2023-01-20 |
ライゼン ファーマシューティカルズ アーゲー |
急性骨髄性白血病の治療のためのdhodh阻害剤を含む組成物
|
EP4051796A1
(en)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
WO2021116874A1
(en)
|
2019-12-10 |
2021-06-17 |
Pfizer Inc. |
Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
|
EP4087649A1
(en)
|
2020-01-11 |
2022-11-16 |
Scholar Rock, Inc. |
Tgfbeta inhibitors and use thereof
|
WO2021142448A2
(en)
|
2020-01-11 |
2021-07-15 |
Scholar Rock,Inc. |
Tgf-beta inhibitors and use thereof
|
CA3166420A1
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Il2 orthologs and methods of use
|
EP4090681A1
(en)
|
2020-01-17 |
2022-11-23 |
Biolegend, Inc. |
Anti-tlr7 agents and compositions and methods for making and using the same
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
TW202140786A
(zh)
|
2020-02-10 |
2021-11-01 |
美商艾爾妮蘭製藥公司 |
用於靜默vegf-a表現之組合物及方法
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
AU2021232062A1
(en)
|
2020-03-06 |
2022-09-29 |
Colorado State University Research Foundation |
Production of vaccines comprising inactivated SARS-CoV-2 viral particles
|
CA3174908A1
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
US20230095383A1
(en)
|
2020-03-17 |
2023-03-30 |
Dst Pharma, Inc. |
Methods and compositions for treating viral infections
|
AU2021244695A1
(en)
|
2020-03-26 |
2022-11-10 |
Plx Opco Inc. |
Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same
|
CA3176569A1
(en)
|
2020-03-27 |
2021-09-30 |
Pfizer Inc. |
Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
|
WO2021202443A2
(en)
|
2020-03-30 |
2021-10-07 |
Alnylam Pharmaceucticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
MX2022012493A
(es)
|
2020-04-06 |
2022-10-27 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para el silenciamiento de la expresion de miocilina (myoc).
|
AU2021251754A1
(en)
|
2020-04-07 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing SCN9A expression
|
EP4132931A1
(en)
|
2020-04-08 |
2023-02-15 |
Pfizer Inc. |
Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
|
CA3176425A1
(en)
|
2020-04-24 |
2021-10-28 |
Millennium Pharmaceuticals, Inc. |
Anti-cd19 antibodies and uses thereof
|
WO2021224850A1
(en)
|
2020-05-06 |
2021-11-11 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
CA3178965A1
(en)
|
2020-05-15 |
2021-11-18 |
Christian COBAUGH |
Messenger rna encoding cas9 for use in genome-editing systems
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
CN115867546A
(zh)
|
2020-05-27 |
2023-03-28 |
上海齐鲁锐格医药研发有限公司 |
Glp-1r激动剂的盐和晶形及其用途
|
MX2022015706A
(es)
|
2020-06-09 |
2023-01-24 |
Pfizer |
Antagonistas del receptor de melanocortina 4 y usos de estos.
|
EP4171632A2
(en)
|
2020-06-26 |
2023-05-03 |
Pfizer Inc. |
Methods of treating inflammatory bowel disease with tl1a antibodies
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
PE20231565A1
(es)
|
2020-07-17 |
2023-10-04 |
Pfizer |
Anticuerpos terapeuticos y sus usos
|
WO2022020811A1
(en)
|
2020-07-24 |
2022-01-27 |
Strand Therapeutics, Inc. |
Lipidnanoparticle comprising modified nucleotides
|
CA3187393A1
(en)
|
2020-07-28 |
2022-02-03 |
Andrew BELFIELD |
Chiral synthesis of fused bicyclic raf inhibitors
|
CA3187514A1
(en)
|
2020-07-28 |
2022-02-03 |
Andrew BELFIELD |
Fused bicyclic raf inhibitors and methods for use thereof
|
JP2023536654A
(ja)
|
2020-08-05 |
2023-08-28 |
シンセカイン インコーポレイテッド |
IL10Ra結合分子および使用方法
|
JP2023536652A
(ja)
|
2020-08-05 |
2023-08-28 |
シンセカイン インコーポレイテッド |
IL27Rα結合分子および使用方法
|
US20230272090A1
(en)
|
2020-08-05 |
2023-08-31 |
Sandro Vivona |
Il2rb binding molecules and methods of use
|
EP4192877A1
(en)
|
2020-08-05 |
2023-06-14 |
Synthekine, Inc. |
Il2rb/il2rg synthetic cytokines
|
AR123156A1
(es)
|
2020-08-06 |
2022-11-02 |
Qilu Regor Therapeutics Inc |
Agonistas de glp-1r y sus usos
|
IL299911A
(en)
|
2020-08-14 |
2023-03-01 |
Kite Pharma Inc |
Improving immune cell function
|
AU2021340793A1
(en)
|
2020-09-14 |
2023-05-11 |
Vor Biopharma Inc. |
Single domain antibodies against cd33
|
EP4213939A1
(en)
|
2020-09-21 |
2023-07-26 |
Boehringer Ingelheim International GmbH |
Use of anti-cd40 antibodies for treatment of inflammatory conditions
|
AU2021357805A1
(en)
|
2020-10-06 |
2023-05-04 |
Xencor, Inc. |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
CA3195264A1
(en)
|
2020-10-14 |
2022-04-21 |
Wenge Zhong |
Crystal forms of glp-1r agonists and uses thereof
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
US11058637B1
(en)
*
|
2020-11-25 |
2021-07-13 |
King Abdulaziz University |
Surface-modified emulsomes for intranasal delivery of drugs
|
IL303195A
(en)
|
2020-11-25 |
2023-07-01 |
Akagera Medicines Inc |
Lipid nanoparticles for delivery of nucleic acids and related methods of use
|
TW202241946A
(zh)
|
2020-12-18 |
2022-11-01 |
美商健生生物科技公司 |
針對整合素α11β1之抗體
|
EP4274846A1
(en)
|
2021-01-08 |
2023-11-15 |
Strand Therapeutics Inc. |
Expression constructs and uses thereof
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
CN117062836A
(zh)
|
2021-02-05 |
2023-11-14 |
勃林格殷格翰国际有限公司 |
抗il1rap抗体
|
CA3208490A1
(en)
|
2021-02-24 |
2022-09-01 |
Aleksandrs Zavoronkovs |
Analogs for the treatment of disease
|
IL305571A
(en)
|
2021-03-11 |
2023-10-01 |
Kite Pharma Inc |
Improving the function of immune system cells
|
WO2022195504A1
(en)
|
2021-03-19 |
2022-09-22 |
Pfizer Inc. |
Method of treating osteoarthritis pain with an anti ngf antibody
|
CA3212056A1
(en)
|
2021-03-22 |
2022-09-29 |
Xavier CHAUCHET |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
US11952461B2
(en)
|
2021-03-22 |
2024-04-09 |
Sunbio, Inc. |
Siloxy polyethylene glycol and derivatives thereof
|
AU2022241935A1
(en)
|
2021-03-22 |
2023-09-28 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
EP4320149A1
(en)
|
2021-04-09 |
2024-02-14 |
Takeda Pharmaceutical Company Limited |
Antibodies targeting complement factor d and uses therof
|
AU2022261124A1
(en)
|
2021-04-22 |
2023-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
IL307939A
(en)
|
2021-04-26 |
2023-12-01 |
Millennium Pharm Inc |
Anti-CLEC12A antibodies and uses thereof
|
IL307940A
(en)
|
2021-04-26 |
2023-12-01 |
Millennium Pharm Inc |
Anti-ADGRE2 antibodies and their uses
|
EP4334354A1
(en)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
US20230115257A1
(en)
|
2021-05-17 |
2023-04-13 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
EP4358995A1
(en)
|
2021-06-23 |
2024-05-01 |
Scholar Rock, Inc. |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
EP4367237A2
(en)
|
2021-07-09 |
2024-05-15 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
TW202306985A
(zh)
|
2021-07-12 |
2023-02-16 |
美商建南德克公司 |
降低抗體-脂酶結合之結構
|
WO2023288277A1
(en)
|
2021-07-14 |
2023-01-19 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgfb1 and uses thereof
|
WO2023007374A1
(en)
|
2021-07-27 |
2023-02-02 |
Pfizer Inc. |
Method of treatment of cancer pain with tanezumab
|
GB202111757D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles for use in the treatment of haemophilia A
|
GB202111758D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles for use in the treatment of haemophilia A
|
GB202111759D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles
|
CN117940422A
(zh)
|
2021-08-31 |
2024-04-26 |
辉瑞大药厂 |
2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸,1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式
|
WO2023034901A1
(en)
|
2021-09-01 |
2023-03-09 |
The Broad Institute, Inc. |
Tumor avatar vaccine compositions and uses thereof
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
AU2022383057A1
(en)
|
2021-11-05 |
2024-05-16 |
Abviro Llc |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
CA3238936A1
(en)
|
2021-11-24 |
2023-06-01 |
Wayne A. Marasco |
Antibodies against ctla-4 and methods of use thereof
|
AU2022403203A1
(en)
|
2021-12-01 |
2024-05-02 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
AU2022403854A1
(en)
|
2021-12-08 |
2024-05-23 |
Array Biopharma Inc. |
Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023111817A1
(en)
|
2021-12-17 |
2023-06-22 |
Pfizer Inc. |
Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
WO2023201238A1
(en)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
Binding agents and methods of use thereof
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023212618A1
(en)
|
2022-04-26 |
2023-11-02 |
Strand Therapeutics Inc. |
Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023228023A1
(en)
|
2022-05-23 |
2023-11-30 |
Pfizer Inc. |
Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
|
WO2023235852A1
(en)
|
2022-06-03 |
2023-12-07 |
Zenas Biopharma, Inc. |
Methods and compositions for treating igg4- related diseases
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024030843A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030845A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030847A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030858A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024030850A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
WO2024084360A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
WO2024084363A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Use of patatin-like phospholipase domain-containing protein 3 compounds
|
WO2024084052A1
(en)
|
2022-10-21 |
2024-04-25 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|
GB202216284D0
(en)
|
2022-11-02 |
2022-12-14 |
Ucl Business Ltd |
Self-regulation
|